Antigen-binding molecules that bind to aav particles and uses

Abstract

Provided herein are anti-adeno-associated virus (AAV) antibodies and antigen fragments thereof, as well as multispecific antibodies (e.g., bispecific antibodies) that bind to both a capsid of an AAV particle and a molecule on a cell surface, related molecular complexes, affinity matrices, and pharmaceutical compositions, and methods of use thereof.

Description

ANTIGEN-BINDING MOLECULES THAT BIND TO AAV PARTICLES AND USESTHEREOFCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 387,876, filed December 16, 2022, U.S. Provisional Application No. 63 / 494,203, filed April 4, 2023, U.S. Provisional Application No. 63 / 520,508, filed August 18, 2023, and U.S. Provisional Application No. 63 / 578,925, filed August 25, 2023, the disclosure of each of which is herein incorporated by reference in its entirety.SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in XML file format and is hereby incorporated by reference in its entirety. Said XML copy, created on December 1 1 , 2023, is named 250298_000568_SL.xml and is 1 ,328,800 bytes in size.FIELD OF THE DISCLOSURE

[0003] The present disclosure relates to antigen-binding molecules, including antibodies or antigen-binding fragments thereof, that bind to a capsid of an adeno-associated virus (AAV) particle. In particular, the disclosure provides multispecific antigen-binding molecules such as multispecific antibodies, e.g., bispecific antibodies, or antigen-binding fragments thereof, that bind to a capsid of an AAV and / or a molecule on a cell surface, as well as related molecular complexes and pharmaceutical compositions. Methods for using the antibodies (e.g., multispecific antibodies) disclosed herein, molecular complexes and / or pharmaceutical composition are also provided.BACKGROUND

[0004] Viral particles have emerged as vectors for gene therapy and the treatment of disease. Viral vectors, such as those based on the genome of adeno-associated virus (AAV), offer promising platforms for gene delivery. Despite advances providing the ability to direct AAV infection, retargeted AAV as a gene delivery vehicle remains less than ideal, at least in part, due to limited success from the efforts to redirect vector tropism. The efficiency of AAV vector-mediated gene delivery to different cell types also varies greatly. One possible mechanism for inefficient AAV transduction of certain cells may be a lack of cellular receptor(s) to mediate virus binding and entry. There remains a need for selective and restrictive targeting of AAVs with enhanced cellular binding and transduction capabilities.SUMMARY OF THE DISCLOSURE

[0005] In general, the present disclosure provides antibodies that bind to a capsid of an adeno-associated virus (AAV) particle, and multispecific antibodies such as, for example, bispecific antibodies, which can bind both to the capsid of an AAV particle and a molecule (i.e., a target molecule) on a cell surface, and methods of use thereof. By binding to both a capsid of an AAV and a target cell surface molecule, the antibodies described herein can bridge the virus to target cell surfaces that are not naturally targeted by the virus, thereby redirecting virus delivery and transduction.

[0006] In one aspect, provided herein is an antibody, or an antigen-binding fragment thereof, wherein said antibody, or said antigen-binding fragment thereof, binds to a capsid of an adeno- associated virus (AAV) particle, and wherein said antibody, or said antigen-binding fragment thereof, comprises: a) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1 159, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1 157; f) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10;g) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or j) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0007] In some embodiments, said antibody, or said antigen-binding fragment thereof, comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 8; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 28; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 38; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 48; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and aLCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 67; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 87; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 97; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or j) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 107; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0008] In some embodiments, said antibody, or said antigen-binding fragment thereof, comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10;c) a HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; f) a HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or j) a HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0009] In another aspect, provided herein is an antibody, or an antigen-binding fragment thereof, wherein said antibody, or said antigen-binding fragment thereof, binds to a capsid of an adeno-associated virus (AAV) particle, wherein said antibody, or said antigen-binding fragment thereof, binds to one or more residues in one or more viral protein 3 (VP3) polypeptides in said capsid, wherein said one or more residues are selected from the residues listed in Tables 18-26.

[0010] In some embodiments, said antibody, or said antigen-binding fragment thereof, binds to a capsid of an AAV2 particle comprising amino acid substitutions R585A and R588A, and wherein the said one or more residues are selected from the following residues in said VP3 polypeptides (according to VP1 numbering): a) S264, A266, N268, H271 , N382, S384, Q385, G512, R487, D494, K527, D529, K532, L538, D533, E555, N705, K706, V708, T450, Q457, and R459; b) S264, G265, A266, S267, N268, H271 , N382, G383, S384, R487, K527, D528, E530, E574, Q575, K706, and S707; c) N254, L256, K258, I260, S261 , Q263, Y272, E322, V323, T324, Q325, A655, A667, S668, F669, I670, T671 , I332, Q545, G546, S547, E548, K556, N717, V719, T660, and F661 ; and / or d) N254, L256, Q263, S264, V323, T324, Q325, S655, A667, S668, F669, I670, T671 , G328, G546, E548, T716, and N717.

[0011] In some embodiments, said antibody, or said antigen-binding fragment thereof, binds to a capsid of an AAV8 particle, and wherein the said one or more residues are selected fromthe following residues in said VP3 polypeptides (according to VP1 numbering): a) N255, L257, K259, 1261 , S262, N263, S266, A269, Y275, E325, V326, T327, Q328, A658, N670, S671 , F672, I673, T674, Q548, N549, A550, A551 , D559, E720, and T663; and / or b) N255, L257, S266, E325, V326, T327, Q328, N670, S671 , F672, I673, T674, N549, T719, and E720.

[0012] In some embodiments, said antibody, or said antigen-binding fragment thereof, binds to a capsid of an AAV9 particle, and wherein the said one or more residues are selected from the following residues in said VP3 polypeptides (according to VP1 numbering): a) N254, I260, N262, Y274, E324, V325, T326, D327, N328, R550, D665, N668, S669, F670, 1671 , T672, Q546, G547, G549, E718, and A661 ; and / or b) N254, L256, I260, N262, E324, V325, T326, D551 , N668, S669, F670, T672, G330, and E718.

[0013] In some embodiments, said antibody, or said antigen-binding fragment thereof, comprises:1) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10;2) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1 159, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1 157;3) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or4) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0014] In some embodiments, said antibody, or said antigen-binding fragment thereof, comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 38; and / or a LCDR1 comprising the amino acid sequence ofSEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 87; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0015] In some embodiments, said antibody, or said antigen-binding fragment thereof, comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or4) a HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0016] In some embodiments of any of the above-described antibodies or antigen-binding fragments, said antibody, or said antigen-binding fragment thereof, is a humanized antibody or antigen binding fragment thereof, human antibody or antigen binding fragment thereof, murine antibody or antigen binding fragment thereof, chimeric antibody or antigen binding fragment thereof, Fab fragment, F(ab')2 fragment, F(ab)'3 fragments, single-chain fragment variable (scFv), bis-scFv, (scFv)2, diabody, minibody, nanobody, triabody, tetrabody, disulfide stabilized Fv protein (dsFv), single-domain antibody (sdAb), Ig NAR, single heavy chain antibody, bispecific antibody, trispecific antibody, or chemically modified derivatives thereof.

[0017] In some embodiments, said antibody, or said antigen-binding fragment thereof, comprises an IgG 1 , lgG2, lgG3, or lgG4 constant region, or a variant thereof.

[0018] In some embodiments, said antibody, or said antigen-binding fragment thereof, comprises an IgG 1 constant region, or a variant thereof.

[0019] In some embodiments, the IgG 1 constant region comprises the amino acid sequence of SEQ ID NO: 259 or 1 164.

[0020] In some embodiments, said antibody, or said antigen-binding fragment thereof, comprises an lgG4 constant region, or a variant thereof.

[0021] In some embodiments, the lgG4 variant comprises a hinge domain modified to reduce binding to Fey receptors.

[0022] In some embodiments, the lgG4 constant region comprises the amino acid sequence of SEQ ID NO: 261.

[0023] In some embodiments, said antigen-binding fragment is a Fab fragment.

[0024] In some embodiments, said antigen-binding fragment is an scFv fragment.

[0025] In some embodiments of any of the above-described antibodies or antigen-binding fragments, said antibody, or said antigen-binding fragment thereof, binds to AAV2 with a dissociation constant (KD) of less than about 1.5 x 10-6M, as measured in a surface plasmon resonance assay.

[0026] In some embodiments, said antibody, or said antigen-binding fragment thereof, binds to AAV2 with a dissociation constant (KD) of less than about 20 nM, as measured in a surface plasmon resonance assay.

[0027] In some embodiments, said capsid comprises one or more wild-type AAV capsid polypeptides.

[0028] In some embodiments, said capsid comprises one or more non-wild-type AAV capsid polypeptides.

[0029] In some embodiments, rein binding of said antibody or antigen-binding fragment thereof to said AAV particle capsid does not neutralize said AAV particle.

[0030] In another aspect, provided herein is an antibody, or an antigen-binding fragment thereof, that binds to the same epitope(s) as any of the above-described antibodies or antigenbinding fragments.

[0031] In another aspect, provided herein is an antibody, or an antigen-binding fragment thereof, that competes for binding to a capsid of an adeno-associated virus (AAV) particle with any of the above-described antibodies or antigen-binding fragments.

[0032] In another aspect, provided herein is a pharmaceutical composition comprising any of the above-described antibodies or antigen-binding fragments and a pharmaceutically acceptable carrier or excipient.

[0033] In another aspect, provided herein is a multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: i) a first antigen-binding domain that binds to a capsid of an adeno-associated virus(AAV) particle; and ii) a second antigen-binding arm that binds to a molecule on a cell surface, wherein said first antigen-binding domain comprises: a) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; f) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, andHCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or j) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0034] In some embodiments, the first antigen-binding domain that binds to a capsid of an AAV particle comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 8; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 28; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 38; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 48; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 67; and / or a LCDR1 comprising the amino acid sequence ofSEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 87; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 97; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or j) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 107; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0035] In some embodiments, the first antigen-binding domain that binds to a capsid of an AAV particle comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; f) a HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 10; h) a HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or j) a HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0036] In another aspect, provided herein is a multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: i) a first antigen-binding domain that binds to a capsid of an adeno-associated virus (AAV) particle, and ii) a second antigen-binding domain that binds to a molecule on a cell surface, wherein said first antigen-binding domain binds to one or more residues in one or more viral protein 3 (VP3) polypeptides in said capsid, wherein said one or more residues are selected from the residues listed in Tables 18-26.

[0037] In some embodiment, said first antigen-binding domain binds to a capsid of an AAV2 particle comprising amino acid substitutions R585A and R588A, and wherein the said one or more residues are selected from the following residues in said VP3 polypeptides (according to VP1 numbering): a) S264, A266, N268, H271 , N382, S384, Q385, G512, R487, D494, K527, K529, K532, L538, D533, E555, N705, K706, V708, T450, Q457, and R459; b) S264, G265, A266, S267, N268, H271 , N382, G383, S384, R487, K527, D528, E530, Q574, Q575, K706, and S707; c) N254, L256, K258, I260, S261 , Q263, Y272, E322, V323, T324, Q325, A655, A667, S668, F669, I670, T671 , I332, Q545, G546, S547, E548, K556, N717, V719, T660, and F661 ; and / or d) N254, L256, Q263, S264, V323, T324, Q325, S655, A667, S668, F669, I670, T671 , G328, G546, E548, T716, and N717.

[0038] In some embodiments, said first antigen-binding domain binds to a capsid of an AAV8 particle, and wherein the said one or more residues are selected from the following residues in said VP3 polypeptides (according to VP1 numbering): e) N255, L257, K259, 1261 , S262, N263, S266, A269, Y275, E325, V326, T327, Q328, A658, N670, S671 , F672, I673, T674, Q548, N549, A550, A551 , D559, E720, and T663; and / or f) N255, L257, S266, E325, V326, T327, Q328, N670, S671 , F672, I673, T674, N549, T719, and E720.

[0039] In some embodiments, said first antigen-binding domain binds to a capsid of an AAV9particle, and wherein the said one or more residues are selected from the following residues in said VP3 polypeptides (according to VP1 numbering): g) N254, I260, N262, Y274, E324, V325, T326, D327, N328, R550, D665, N668, S669, F670, 1671 , T672, Q546, G547, G549, E718, and A661 ; and / or h) N254, L256, I260, N262, E324, V325, T326, D551 , N668, S669, F670, T672, G330, and E718.

[0040] In some embodiments, said first antigen-binding domain that binds to a capsid of an AAV particle comprises:1) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10;2) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1 159, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1 157;3) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or4) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0041] In some embodiments, said first antigen-binding domain that binds to a capsid of an AAV particle comprises :1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 38; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 87; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0042] In some embodiments, said first antigen-binding domain that binds to a capsid of an AAV particle comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1 159, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1 157;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or4) a HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0043] In some embodiments of any of the above-described multispecific antibodies or multispecific antigen-binding fragments, the molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel auxiliary subunit gamma 1 (CACNG1).

[0044] In some embodiments, the molecule on the cell surface is ASGR1 .

[0045] In some embodiments, the second antigen-binding domain that binds to ASGR1 comprises: a) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; or b) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0046] In some embodiments, said second antigen-binding domain that binds to ASGR1 comprises:a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 226; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 236; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0047] In some embodiments, said second antigen-binding domain that binds to ASGR1 comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; or b) a HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0048] In some embodiments, the molecule on the cell surface is TfR.

[0049] In some embodiments, the second antigen-binding domain that binds to TfR comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR that comprises theLCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 319 or 320;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 377;1 1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acidsequence of SEQ ID NO: 419;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 511 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599;32) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within anHCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

[0050] In some embodiments, said second antigen-binding domain that binds to TfR comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 274; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 279;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 285; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 290;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 296; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 301 ;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 306; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 311 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 312;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 317; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 321 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 323;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 329; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 335;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and a HCDR3 comprising the aminoacid sequence of SEQ ID NO: 341 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 347;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 351 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 353; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 359;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 364; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 369;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 375; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 380;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 385; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 390;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 396; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 401 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 402;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 407; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 411 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 412;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 417; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 421 , and aLCDR3 comprising the amino acid sequence of SEQ ID NO: 422;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 428; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 434;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 439; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 444;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 450; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 455;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 460; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 465;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 471 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 477;20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 481 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 483; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 488;21) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 494; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 499;22) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, a HCDR2comprising the amino acid sequence of SEQ ID NO: 503, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 504; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 509;23) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 514; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 519;24) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 524; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 529;25) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 534; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 539;26) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 545; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 550;27) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 555; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 560;28) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 565; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 570;29) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 575; and / or a LCDR1 comprising the amino acid sequence ofSEQ ID NO: 578, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 580;30) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 585; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 590;31) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 596; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 601 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 602;32) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 607; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 611 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 613; or33) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1121 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1123, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1125; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1129, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1131 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1133.

[0051] In some embodiments, the second antigen-binding domain that binds to TfR comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 319 or 320;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or aLCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 377;11) a HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR comprising the amino acid sequence of SEQ ID NO: 511 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599;32) a HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR comprising the amino acid sequence of SEQ ID NO: 1 119, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1 127.

[0052] In some embodiments, the molecule on the cell surface is CACNG1 .

[0053] In some embodiments, the antigen-binding domain that binds to CACNG1 comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequenceof SEQ ID NO: 703;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 803;1 1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0054] In some embodiments, the second antigen-binding domain that binds to CACNG1 comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 621 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 629;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 641 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 649;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, a HCDR2comprising the amino acid sequence of SEQ ID NO: 659, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 661 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 669;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 681 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 689;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 701 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 709;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 721 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 729;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 741 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 745, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 749;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 761 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 769;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 781 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 789;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 801 ; and / or a LCDR1 comprising the amino acid sequence ofSEQ ID NO: 805, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 809;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 821 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 829;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 841 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 849;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 861 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 869;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 881 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 889;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 901 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 909;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 921 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 929;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 941 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 949;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 961 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 969;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1183, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1185, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1187; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1191 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1193, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195; or20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1207, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1209, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1211 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1215, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1217, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1219.

[0055] In some embodiments, the second antigen-binding domain that binds to CACNG1 comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 803;1 1) a HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 1 181 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or20) a HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0056] In another aspect, provided herein is a multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1”) operably linked to (ii) a second heavy chain region of a second Fab (“Fab2”); b) a second polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a first antigen-binding domain (“ABD1”); and c) a third polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain (“ABD2”); wherein ABD1 or ABD2 binds to a capsid of an adeno-associated virus (AAV) particle, and the other of ABD1 or ABD2 binds to a molecule on a cell surface.

[0057] In some embodiments, ABD1 binds to a capsid of an adeno-associated virus (AAV) particle and ABD2 binds to a molecule on the cell surface.

[0058] In some embodiments, ABD2 binds to a capsid of an adeno-associated virus (AAV) particle and ABD1 binds to a molecule on the cell surface.

[0059] In some embodiments, the first heavy chain region is linked to the second heavychain region via a linker.

[0060] In another aspect, provided herein is a multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first scFv comprising a first antigen-binding domain (“ABD1”) operably linked to (ii) an Fc domain; b) a second polypeptide chain, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1 ”) operably linked to (ii) an Fc domain; and c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a second antigen-binding domain (“ABD2”); wherein ABD1 or ABD2 binds to a capsid of an adeno-associated virus (AAV) particle, and the other of ABD1 or ABD2 binds to a molecule on a cell surface.

[0061] In some embodiments, ABD1 binds to a capsid of an adeno-associated virus (AAV) particle and ABD2 binds to a molecule on the cell surface.

[0062] In some embodiments, ABD2 binds to a capsid of an adeno-associated virus (AAV) particle and ABD1 binds to a molecule on the cell surface.

[0063] In some embodiments, the first scFv and / or the first heavy chain region is linked to the Fc domain via a linker.

[0064] In some embodiments, the ABD1 or ABD2 which binds to a capsid of an AAV particle comprises: a) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or1159, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; f) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; and / or j) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0065] In some embodiments, the ABD1 or ABD2 which binds to a capsid of an AAV particle comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 8; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 28; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and a HCDR3 comprising the aminoacid sequence of SEQ ID NO: 38; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 48; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 67; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 87; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 97; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; and / or j) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 107; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and aLCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0066] In some embodiments, the ABD1 or ABD2 which binds to a capsid of an AAV particle comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1 159, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; f) a HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; and / or j) a HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0067] In some embodiments, the molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel auxiliary subunit gamma 1 (CACNG1).

[0068] In some embodiments, the molecule on the cell surface is ASGR1 .

[0069] In some embodiments, the other of ABD1 or ABD2 which binds to ASGR1 comprises: a) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; or b) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0070] In some embodiments, the other of ABD1 or ABD2 which binds to ASGR1 comprises:a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 226; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 236; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0071] In some embodiments, the other of ABD1 or ABD2 which binds to ASGR1 comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; or b) a HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0072] In some embodiments, the molecule on the cell surface is TfR.

[0073] In some embodiments, the other of ABD1 or ABD2 which binds to TfR comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequenceof SEQ ID NO: 319 or 320;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 377;1 1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 511 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within anHCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599;32) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 11 19, and / or a LCVR thatcomprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

[0074] In some embodiments, the other of ABD1 or ABD2 which binds to TfR comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 274; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 279;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 285; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 290;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 296; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 301 ;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 306; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 311 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 312;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 317; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 321 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 323;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 329; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 335;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 341 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and aLCDR3 comprising the amino acid sequence of SEQ ID NO: 347;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 351 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 353; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 359;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 364; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 369;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 375; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 380;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 385; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 390;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 396; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 401 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 402;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 407; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 411, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 412;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 417; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 421 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 422;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, a HCDR2comprising the amino acid sequence of SEQ ID NO: 427, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 428; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 434;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 439; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 444;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 450; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 455;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 460; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 465;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 471 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 477;20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 481 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 483; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 488;21) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 494; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 499;22) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 503, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 504; and / or a LCDR1 comprising the amino acid sequence ofSEQ ID NO: 507, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 509;23) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 514; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 519;24) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 524; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 529;25) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 534; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 539;26) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 545; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 550;27) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 555; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 560;28) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 565; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 570;29) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 575; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 578, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 580;30) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 585; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 590;31) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 596; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 601 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 602;32) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 607; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 611 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 613; or33) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1121 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1123, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1125; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1129, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1131 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1133.

[0075] In some embodiments, the other of ABD1 or ABD2 which binds to TfR comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 319 or 320;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 377;11) a HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR comprising the amino acid sequence of SEQ ID NO: 511 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599 ;32) a HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR comprising the amino acid sequence of SEQ ID NO: 1 119, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1 127.

[0076] In some embodiments, the molecule on the cell surface is CACNG1 .

[0077] In some embodiments, the other of ABD1 or ABD2 which binds to CACNG1 comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVRcomprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 803;1 1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR that comprisesthe LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0078] In some embodiments, the other of ABD1 or ABD2 which binds to CACNG1 comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 621 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 629;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 641 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 649;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 661 ; and / or a LCDR1 comprising the amino acid sequence ofSEQ ID NO: 665, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 669;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 681 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 689;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 701 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 709;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 721 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 729;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 741 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 745, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 749;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 761 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 769;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 781 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 789;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 801 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 809;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 821 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 829;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 841 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 849;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 861 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 869;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 881 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 889;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 901 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 909;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 921 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 929;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 941 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 949;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and a HCDR3 comprising the aminoacid sequence of SEQ ID NO: 961 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 969;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1183, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1185, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1187; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1191 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1193, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195; or20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1207, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1209, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1211 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1215, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1217, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1219.

[0079] In some embodiments, the other of ABD1 or ABD2 which binds to CACNG1 comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 803;11) a HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 1 181 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1 189; or20) a HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0080] In another aspect, provided herein is a multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) an scFv comprising a first antigen-binding domain (“ABD1 ”) operably linked to (ii) a first heavy chain region of a first Fab (“Fab1”), said first heavy chain region operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a second heavy chain region of a second Fab (“Fab2”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a second antigen-binding domain (“ABD2”); and d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain (“ABD3”); wherein at least one of ABD1 , ABD2 and ABD3 binds to a capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1 , ABD2 and ABD3 bind to a molecule on a cell surface.

[0081] In some embodiments, two of ABD1 , ABD2 and ABD3 bind to a capsid of an AAV particle, and one of ABD1 , ABD2 and ABD3 binds to a molecule on a cell surface.

[0082] In some embodiments, ABD2 and ABD3 bind to a capsid of an AAV particle, and ABD1 binds to a molecule on a cell surface.

[0083] In some embodiments, ABD1 and ABD3 bind to a capsid of an AAV particle, and ABD2 binds to a molecule on a cell surface.

[0084] In some embodiments, the scFv is linked to the first heavy chain region via a linker.

[0085] In another aspect, provided herein is a multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1 ”) operably linked to (ii) an Fc domain, said Fc domain operably linked to (iii) an scFv comprising a first antigen-binding domain (“ABD1”); b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a second heavy chain region of a second Fab (“Fab2”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a second antigen-binding domain (“ABD2”); and d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain (“ABD3”); wherein at least one of ABD1 , ABD2 and ABD3 binds to a capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1 , ABD2 and ABD3 bind to a molecule on a cell surface.

[0086] In some embodiments, two of ABD1 , ABD2 and ABD3 bind to a capsid of an AAV particle, and one of ABD1 , ABD2 and ABD3 binds to a molecule on a cell surface.

[0087] In some embodiments, ABD2 and ABD3 bind to a capsid of an AAV particle, and ABD1 binds to a molecule on a cell surface.

[0088] In some embodiments, ABD1 and ABD2 bind to a capsid of an AAV particle, and ABD3 binds to a molecule on a cell surface.

[0089] In some embodiments, the scFv is linked to the Fc domain via a linker.

[0090] In another aspect, provided herein is a multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1”) operably linked to (ii) a second heavy chain region of a second Fab (“Fab2”), said second heavy chain region of Fab2 operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a third heavy chain region of a third Fab (“Fab3”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a first antigen-binding domain (“ABD1 ”); d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain(“ABD2”); and e) a fifth polypeptide chain comprising a third light chain that pairs with the third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain (“ABD3”); wherein at least one of ABD1 , ABD2 and ABD3 binds to a capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1 , ABD2 and ABD3 bind to a molecule on a cell surface.

[0091] In some embodiments, two of ABD1 , ABD2 and ABD3 bind to a capsid of an AAV particle, and one of ABD1 , ABD2 and ABD3 binds to a molecule on a cell surface.

[0092] In some embodiments, ABD2 and ABD3 bind to a capsid of an AAV particle, and ABD1 binds to a molecule on a cell surface.

[0093] In some embodiments, ABD1 and ABD3 bind to a capsid of an AAV particle, and ABD2 binds to a molecule on a cell surface.

[0094] In some embodiments, the first heavy chain region is linked to the second heavy chain region via a linker.

[0095] In another aspect, provided herein is a multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1 ”) operably linked to (ii) an Fc domain, said Fc domain operably linked to (iii) a second heavy chain region of a second Fab (“Fab2”); b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a third heavy chain region of a third Fab (“Fab3”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a first antigen-binding domain (“ABD1 ”); d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain (“ABD2”); and e) a fifth polypeptide chain comprising a third light chain that pairs with the third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain (“ABD3”); wherein at least one of ABD1 , ABD2 and ABD3 binds to a capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1 , ABD2 and ABD3 bind to a molecule on a cell surface.

[0096] In some embodiments, two of ABD1 , ABD2 and ABD3 bind to a capsid of an AAV particle, and one of ABD1 , ABD2 and ABD3 binds to a molecule on a cell surface.

[0097] In some embodiments, ABD1 and ABD3 bind to a capsid of an AAV particle, and ABD2 binds to a molecule on a cell surface.

[0098] In some embodiments, ABD1 and ABD2 bind to a capsid of an AAV particle, and ABD3 binds to a molecule on a cell surface.

[0099] In some embodiments, the second heavy chain region is linked to the Fc domain via a linker.

[0100] In another aspect, provided herein is a multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1”) operably linked to (ii) an scFv comprising a first antigen-binding domain (“ABD1 ”), said scFv operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a second heavy chain region of a second Fab (“Fab2”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a second antigen-binding domain (“ABD2”); and d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain (“ABD3”); wherein at least one of ABD1 , ABD2 and ABD3 binds to a capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1 , ABD2 and ABD3 bind to a molecule on a cell surface.

[0101] In some embodiments, two of ABD1 , ABD2 and ABD3 bind to a capsid of an AAV particle, and one of ABD1 , ABD2 and ABD3 binds to a molecule on a cell surface.

[0102] In some embodiments, ABD2 and ABD3 bind to a capsid of an AAV particle, and ABD1 binds to a molecule on a cell surface.

[0103] In some embodiments, ABD1 and ABD2 bind to a capsid of an AAV particle, and ABD3 binds to a molecule on a cell surface.

[0104] In some embodiments, the scFv is linked to the first heavy chain region via a linker.

[0105] In another aspect, provided herein is a multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1 ”) operably linked to (ii) an Fc domain, said Fc domain operably linked to (iii) a second heavy chain region of a second Fab (“Fab2”); b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) an scFv comprising a first antigen-binding domain (“ABD1 ”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a second antigen-binding domain (“ABD2”); and d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain (“ABD3”); wherein at least one of ABD1 , ABD2 and ABD3 binds to a capsid of an adeno-associatedvirus (AAV) particle, and the other(s) of ABD1 , ABD2 and ABD3 bind to a molecule on a cell surface.

[0106] In some embodiments, two of ABD1 , ABD2 and ABD3 bind to a capsid of an AAV particle, and one of ABD1 , ABD2 and ABD3 binds to a molecule on a cell surface.

[0107] In some embodiments, ABD2 and ABD3 bind to a capsid of an AAV particle, and ABD1 binds to a molecule on a cell surface.

[0108] In some embodiments, ABD1 and ABD2 bind to a capsid of an AAV particle, and ABD3 binds to a molecule on a cell surface.

[0109] In some embodiments, the second heavy chain region is linked to the Fc domain via a linker.

[0110] In another aspect, provided herein is a multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1”) operably linked to (ii) a second heavy chain region of a second Fab (“Fab2”), said second heavy chain region operably linked to (iii) a third heavy chain region of a third Fab (“Fab3”); b) a second polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a first antigen-binding domain (“ABD1”); and c) a third polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain (“ABD2”); d) a fourth polypeptide chain comprising a third light chain that pairs with the third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain (“ABD3”); wherein at least one of ABD1 , ABD2, and ABD3 binds to a capsid of an adeno- associated virus (AAV) particle, and the other(s) of ABD1 , ABD2 and ABD3 bind to a molecule on a cell surface.

[0111] In some embodiments, two of ABD1 , ABD2 and ABD3 bind to a capsid of an AAV particle, and one of ABD1 , ABD2 and ABD3 binds to a molecule on a cell surface.

[0112] In some embodiments, ABD2 and ABD3 bind to a capsid of an AAV particle, and ABD1 binds to a molecule on a cell surface.

[0113] In some embodiments, ABD1 and ABD3 bind to a capsid of an AAV particle, and ABD2 binds to a molecule on a cell surface.

[0114] In some embodiments, the first heavy chain region is operably linked to the second heavy chain region and / or the second heavy chain region is operably linked to the third heavy chain region via a linker.

[0115] In some embodiments, the at least one of ABD1 , ABD2 and ABD3 which binds to acapsid of an AAV particle comprises: a) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; f) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; and / or j) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0116] In some embodiments, the at least one of ABD1 , ABD2 and ABD3 which binds to a capsid of an AAV particle comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 8; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 28; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 38; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 48; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 67; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16;g) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 87; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 97; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; and / or j) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 107; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0117] In some embodiments, the at least one of ABD1 , ABD2 and ABD3 which binds to a capsid of an AAV particle comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; f) a HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 10; i) a HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; and / or j) a HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0118] In some embodiments, said molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel auxiliary subunit gamma 1 (CACNG1).

[0119] In some embodiments, said molecule on the cell surface is ASGR1.

[0120] In some embodiments, the other(s) of ABD1 , ABD2 and ABD3 which binds to ASGR1 comprises: a) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; or b) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0121] In some embodiments, the other(s) of ABD1 , ABD2 and ABD3 which binds to ASGR1 comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 226; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 236; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0122] In some embodiments, the other(s) of ABD1 , ABD2 and ABD3 which binds to ASGR1 comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; or b) a HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0123] In some embodiments, the molecule on the cell surface is TfR.

[0124] In some embodiments, the other(s) of ABD1 , ABD2 and ABD3 which binds to TfR comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 319 or 320;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR that comprises theLCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 377;1 1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acidsequence of SEQ ID NO: 462;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 511 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599;32) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 11 19, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

[0125] In some embodiments, the other(s) of ABD1 , ABD2 and ABD3 which binds to TfR comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 274; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 279;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 285; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 290;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, a HCDR2comprising the amino acid sequence of SEQ ID NO: 295, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 296; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 301 ;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 306; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 311 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 312;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 317; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 321 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 323;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 329; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 335;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 341 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 347;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 351 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 353; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 359;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 364; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 369;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 375; and / or a LCDR1 comprising the amino acid sequence ofSEQ ID NO: 378, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 380;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 385; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 390;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 396; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 401 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 402;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 407; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 411 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 412;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 417; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 421 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 422;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 428; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 434;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 439; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 444;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 450; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 455;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 460; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 465;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 471 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 477;20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 481 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 483; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 488;21) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 494; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 499;22) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 503, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 504; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 509;23) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 514; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 519;24) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 524; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 529;25) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and a HCDR3 comprising the aminoacid sequence of SEQ ID NO: 534; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 539;26) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 545; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 550;27) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 555; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 560;28) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 565; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 570;29) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 575; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 578, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 580;30) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 585; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 590;31) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 596; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 601 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 602;32) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 607; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 611 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and aLCDR3 comprising the amino acid sequence of SEQ ID NO: 613; or33) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1121 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1123, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1125; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1129, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1 131 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1133.

[0126] In some embodiments, the other(s) of ABD1 , ABD2 and ABD3 which binds to TfR comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 319 or 320;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 377;1 1) a HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / ora LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR comprising the amino acid sequence of SEQ ID NO: 51 1 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599 ;32) a HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR comprising the amino acid sequence of SEQ ID NO: 1 119, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1 127.

[0127] In some embodiments, the molecule on the cell surface is CACNG1 .

[0128] In some embodiments, the other(s) of ABD1 , ABD2 and ABD3 which binds to CACNG1 comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR thatcomprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 803;11) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the aminoacid sequence of SEQ ID NO: 963;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0129] In some embodiments, the other(s) of ABD1 , ABD2 and ABD3 which binds to CACNG1 comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 621 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 629;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 641 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 649;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 661 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 669;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 681 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 689;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 701 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 709;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, a HCDR2comprising the amino acid sequence of SEQ ID NO: 719, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 721 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 729;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 741 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 745, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 749;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 761 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 769;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 781 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 789;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 801 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 809;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 821 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 829;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 841 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 849;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 861 ; and / or a LCDR1 comprising the amino acid sequence ofSEQ ID NO: 865, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 869;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 881 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 889;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 901 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 909;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 921 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 929;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 941 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 949;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 961 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 969;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 183, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1185, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1187; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1191 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1 193, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195; or20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1207, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1209, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 121 1 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1215, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1217, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1219.

[0130] In some embodiments, the other(s) of ABD1 , ABD2 and ABD3 which binds toCACNG1 comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 803;11) a HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 1 181 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1 189; or20) a HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0131] In another aspect, provided herein is a multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first scFv comprising a first antigen-binding domain (“ABD1 ”) operably linked to (ii) a first heavy chain region of a first Fab (“Fab1 ”), said first heavy chain region of Fab1 operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a second scFv comprising a second antigen-binding domain (“ABD2”) operably linked to (ii) a second heavy chain region of a second Fab (“Fab2”), said second heavy chain region of Fab2 operably linked to (iii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a third antigen-binding domain (“ABD3”); d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a fourth antigen-binding domain (“ABD4”); wherein at least one of ABD1 , ABD2, ABD3 and ABD4 binds to a capsid of an adeno- associated virus (AAV) particle, and the other(s) of ABD1 , ABD2, ABD3, and ABD4 bind to a molecule on a cell surface.

[0132] In some embodiments, two of ABD1 , ABD2, ABD3, and ABD4 bind to a capsid of an AAV particle, and two of ABD1 , ABD2, ABD3 and ABD4 binds to a molecule on a cell surface.

[0133] In some embodiments, ABD1 and ABD2 bind to a capsid of an AAV particle, and ABD3 and ABD4 binds to a molecule on a cell surface.

[0134] In some embodiments, ABD3 and ABD4 bind to a capsid of an AAV particle, and ABD1 and ABD2 binds to a molecule on a cell surface.

[0135] In some embodiments, the first scFv is linked to the first heavy chain region and / or the second scFv is linked to the second heavy chain region via a linker.

[0136] In another aspect, provided herein is a multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1 ’’) operably linked to (ii) an Fc domain, said Fc domain operably linked to (iii) a first scFv comprising a first antigen-binding domain (“ABD1 ”); b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) asecond heavy chain region of a second Fab (“Fab2”) operably linked to (ii) an Fc domain, said Fc domain operably linked to (iii) a second scFv comprising a second antigen-binding domain (“ABD2”); c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a third antigen-binding domain (“ABD3”); d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a fourth antigen-binding domain (“ABD4”); wherein at least one of ABD1 , ABD2, ABD3 and ABD4 binds to a capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1 , ABD2, ABD3, and ABD4 bind to a molecule on a cell surface.

[0137] In some embodiments, two of ABD1 , ABD2, ABD3, and ABD4 bind to a capsid of an AAV particle, and two of ABD1 , ABD2, ABD3 and ABD4 binds to a molecule on a cell surface.

[0138] In some embodiments, ABD1 and ABD2 bind to a capsid of an AAV particle, and ABD3 and ABD4 binds to a molecule on a cell surface.

[0139] In some embodiments, ABD3 and ABD4 bind to a capsid of an AAV particle, and ABD1 and ABD2 binds to a molecule on a cell surface.

[0140] In some embodiments, the first scFv and / or second scFv is linked to the Fc domain via a linker.

[0141] In another aspect, provided herein is a multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1”) operably linked to (ii) a second heavy chain region of a second Fab (“Fab2”) operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a third heavy chain region of a third Fab (“Fab3) operable liked to (ii) a fourth heavy chain region of a fourth Fab (“Fab4”) operably linked to (iii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a first antigen-binding domain (“ABD1 ”); d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain (“ADB2”); e) a fifth polypeptide chain comprising a third light chain that pairs with the third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain (“ABD3”); and f) a sixth polypeptide chain comprising a fourth light chain that pairs with the fourth heavy chain region to form Fab4, wherein Fab 4 comprises a fourth antigen-binding domain (“ABD4”); wherein at least one of ABD1 , ABD2, ABD3 and ABD4 binds to a capsid of anadeno-associated virus (AAV) particle, and the other(s) of ABD1 , ABD2, ABD3, and ABD4 bind to a molecule on a cell surface.

[0142] In some embodiments, two of ABD1 , ABD2, ABD3, and ABD4 bind to a capsid of an AAV particle, and two of ABD1 , ABD2, ABD3 and ABD4 binds to a molecule on a cell surface.

[0143] In some embodiments, ABD1 and ABD3 bind to a capsid of an AAV particle, and ABD2 and ABD4 binds to a molecule on a cell surface.

[0144] In some embodiments, ABD2 and ABD4 bind to a capsid of an AAV particle, and ABD1 and ABD3 binds to a molecule on a cell surface.

[0145] In some embodiments, the first heavy chain region is linked to the second heavy chain region and / or the third heavy chain region is linked to fourth heavy chain region via a linker.

[0146] In some embodiments, the at least one of ABD1 , ABD2, ABD3, and ABD4 which binds to a capsid of an AAV particle comprises: a) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; f) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; and / or j) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0147] In some embodiments, the at least one of ABD1 , ABD2, ABD3, and ABD4 which binds to a capsid of an AAV particle comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 8; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 28; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 38; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 48; and / or a LCDR1 comprising the amino acid sequence ofSEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 67; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 87; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 97; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; and / or j) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 107; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0148] In some embodiments, the at least one of ABD1 , ABD2, ABD3, and ABD4 which binds to a capsid of an AAV particle comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 10; c) a HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; f) a HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; and / or j) a HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0149] In some embodiments, said molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel auxiliary subunit gamma 1 (CACNG1).

[0150] In some embodiments, said molecule on the cell surface is ASGR1 .

[0151] In some embodiments, the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to ASGR1 comprises: a) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; or b) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0152] In some embodiments, the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to ASGR1 comprises a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 226; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and aLCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 236; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0153] In some embodiments, the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to ASGR1 comprises a) a HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; or b) a HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0154] In some embodiments, said molecule on the cell surface is TfR.

[0155] In some embodiments, the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to TfR comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 319 or 320;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVR thatcomprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 377;11) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the aminoacid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 511 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599;32) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

[0156] In some embodiments, the other(s) of ABD1 , ABD2, ABD3, and ABD4 which bindsto TfR comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 274; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 279;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 285; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 290;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 296; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 301 ;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 306; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 311 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 312;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 317; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 321 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 323;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 329; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 335;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 341 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 347;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 351 , a HCDR2comprising the amino acid sequence of SEQ ID NO: 352, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 353; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 359;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 364; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 369;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 375; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 380;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 385; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 390;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 396; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 401 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 402;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 407; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 411 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 412;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 417; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 421 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 422;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 428; and / or a LCDR1 comprising the amino acid sequence ofSEQ ID NO: 432, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 434;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 439; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 444;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 450; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 455;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 460; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 465;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 471 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 477;20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 481 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 483; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 488;21) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 494; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 499;22) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 503, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 504; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 509;23) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 514; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 519;24) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 524; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 529;25) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 534; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 539;26) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 545; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 550;27) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 555; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 560;28) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 565; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 570;29) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 575; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 578, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 580;30) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and a HCDR3 comprising the aminoacid sequence of SEQ ID NO: 585; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 590;31) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 596; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 601 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 602;32) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 607; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 61 1 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 613; or33) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 121 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1123, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1125; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1129, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1 131 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1133.

[0157] In some embodiments, the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to TfR comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 319 or 320;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 377;11) a HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR comprising the amino acid sequence of SEQ ID NO: 511 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599 ;32) a HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR comprising the amino acid sequence of SEQ ID NO: 1 119, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1 127.

[0158] In some embodiments, said molecule on the cell surface is CACNG1 .

[0159] In some embodiments, the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to CACNG1 comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR thatcomprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 803;11) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the aminoacid sequence of SEQ ID NO: 903;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0160] In some embodiments, the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to CACNG1 comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 621 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 629;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 641 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 649;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 661 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and aLCDR3 comprising the amino acid sequence of SEQ ID NO: 669;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 681 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 689;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 701 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 709;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 721 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 729;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 741 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 745, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 749;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 761 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 769;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 781 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 789;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 801 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 809;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, a HCDR2comprising the amino acid sequence of SEQ ID NO: 819, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 821 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 829;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 841 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 849;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 861 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 869;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 881 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 889;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 901 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 909;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 921 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 929;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 941 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 949;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 961 ; and / or a LCDR1 comprising the amino acid sequence ofSEQ ID NO: 965, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 969;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 183, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1185, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1187; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1191 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1 193, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195; or20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1207, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1209, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 121 1 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1215, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1217, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1219.

[0161] In some embodiments, the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to CACNG1 comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 803;1 1) a HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 1 181 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1 189; or20) a HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0162] In some embodiments, the linker is:(a) at least 5 amino acids, at least 6 amino acids or at least 7 amino acids in length; and optionally(b) up to 30 amino acids, up to 40 amino acids, up to 50 amino acids or up to 60 amino acids in length.

[0163] In some embodiments, the linker is:(a) 5 amino acids to 50 amino acids in length;(b) 5 amino acids to 45 amino acids in length;(c) 5 amino acids to 40 amino acids in length;(d) 5 amino acids to 35 amino acids in length;(e) 5 amino acids to 30 amino acids in length;(f) 5 amino acids to 25 amino acids in length; or(g) 5 amino acids to 20 amino acids in length.

[0164] In some embodiments, the linker is:(a) 6 amino acids to 50 amino acids in length;(b) 6 amino acids to 45 amino acids in length;(c) 6 amino acids to 40 amino acids in length;(d) 6 amino acids to 35 amino acids in length;(e) 6 amino acids to 30 amino acids in length;(f) 6 amino acids to 25 amino acids in length; or(g) 6 amino acids to 20 amino acids in length.

[0165] In some embodiments, the linker is:(a) 7 amino acids to 40 amino acids in length;(b) 7 amino acids to 35 amino acids in length;(c) 7 amino acids to 30 amino acids in length;(d) 7 amino acids to 25 amino acids in length;(e) 7 amino acids to 20 amino acids in length.

[0166] In some embodiments, the linker is 5 amino acids to 25 amino acids in length.

[0167] In some embodiments, the linker is 10 amino acids to 60 amino acids in length.

[0168] In some embodiments, the linker is 20 amino acids to 50 amino acids in length.

[0169] In some embodiments, the linker is 25 to 35 amino acids in length.

[0170] In some embodiments, the linker is or comprises a multimer of GnS (SEQ ID NO:239) or SGn (SEQ ID NO: 240), where n is an integer from 1 to 10.

[0171] In some embodiments, the linker is or comprises a multimer of G4S (SEQ ID NO: 242).

[0172] In some embodiments, the linker is or comprises two consecutive glycines (2Gly), three consecutive glycines (3Gly), four consecutive glycines (4Gly (SEQ ID NO: 243)), five consecutive glycines (5Gly (SEQ ID NO: 244)), six consecutive glycines (6Gly (SEQ ID NO: 245)), seven consecutive glycines (7Gly (SEQ ID NO: 246)), eight consecutive glycines (8Gly (SEQ ID NO: 247)) or nine consecutive glycines (9Gly (SEQ ID NO: 248)).

[0173] In some embodiments, one or more light chains are universal light chains.

[0174] In some embodiments, a light chain constant region (CL) and a first heavy chain constant region (CH1) of one or more Fabs are in a CrossmAb arrangement.

[0175] In some embodiments of any of the above-described multispecific antibodies or multispecific antigen-binding fragments, the multispecific antibodies or multispecific antigenbinding fragments comprise an Fc heterodimer.

[0176] In some embodiments, the Fc domains in the Fc heterodimer comprise knob-in-hole mutations as compared to a wild-type Fc domain.

[0177] In some embodiments, one Fc domain in the Fc heterodimer comprises amino acid substitutions S354C and T366W (according to EU numbering) as compared to a wild-type Fc domain, and the other Fc domain in the Fc heterodimer comprises amino acid substitutions Y349C, T366S, L368A, and Y407V (according to EU numbering) as compared to a wild-type Fc domain.

[0178] In some embodiments, at least one Fc domain in the Fc heterodimer comprises a star mutation as compared to a wild-type Fc domain.

[0179] In some embodiments, one Fc domain in the Fc heterodimer comprises amino acid mutations H435R and / or Y436F (according to EU numbering) as compared to a wild-type Fcdomain.

[0180] In some embodiments, said capsid comprises one or more wild-type AAV capsid polypeptides.

[0181] In some embodiments, said capsid comprises one or more non-wild-type AAV capsid polypeptides.

[0182] In some embodiments of any of the above-described multispecific antibodies or multispecific antibody fragments, the multispecific antibodies or multispecific antigen-binding fragments can be a bispecific antibody or bispecific antigen-binding fragment thereof.

[0183] In another aspect, provided herein is a pharmaceutical composition comprising a multispecific antibody or multispecific antigen-binding fragment described herein, and a pharmaceutically acceptable carrier or excipient.

[0184] In another aspect, provided herein is a molecular complex comprising an AAV particle bound to one or more antibodies and / or antigen-binding fragments described herein.

[0185] In some embodiments, said AAV particle comprises one or more mutations in one or more AAV capsid proteins inhibiting the natural tropism of said AAV particle.

[0186] In another aspect, provided herein is a pharmaceutical composition comprising a molecular complex described herein and a pharmaceutically acceptable carrier or excipient.

[0187] In another aspect, provided herein is a method of preparing the molecular complex described herein, comprising incubating said AAV particle in the presence of said one or more antibodies and / or antigen-binding fragments under conditions allowing specific binding of said one or more antibodies and / or antigen-binding fragments to said AAV particle capsid.

[0188] In another aspect, provided herein is a molecular complex comprising an AAV particle bound to one or more multispecific antibodies and / or multispecific antigen-binding fragments described herein.

[0189] In some embodiments, said AAV particle comprises one or more mutations in one or more AAV capsid proteins inhibiting the natural tropism of said AAV particle.

[0190] In another aspect, provided herein is a pharmaceutical composition comprising a molecular complex described herein and a pharmaceutically acceptable carrier or excipient.

[0191] In another aspect, provided herein is a method of preparing a molecular complex described herein, comprising incubating said AAV particle in the presence of said one or more multispecific antibodies and / or multispecific antigen-binding fragments under conditions allowing specific binding of said one or more multispecific antibodies and / or multispecific antigen-binding fragments to said AAV particle capsid.

[0192] In another aspect, provided herein is a method for targeting an AAV particle to a cell expressing a molecule on the cell surface, comprising contacting the cell with a molecular complex described herein or a pharmaceutical composition described herein, wherein said molecular complex comprises one or more multispecific antibodies and / or multispecificantigen-binding fragments which bind to said molecule on the cell surface.

[0193] In another aspect, provided herein is a method for delivering a polynucleotide to a cell expressing a molecule on the cell surface, comprising contacting the cell with a molecular complex described herein or a pharmaceutical composition described herein, wherein said molecular complex comprises the AAV particle comprising said polynucleotide and bound to one or more multispecific antibodies and / or multispecific antigen-binding fragments which bind to said molecule on the cell surface.

[0194] In some embodiments, said cell is in a subject and said molecular complex is administered to the subject.

[0195] In some embodiments, said AAV particle does not target said cell in the absence of said one or more multispecific antibodies and / or multispecific antigen-binding fragments.

[0196] In various embodiments, any of the features or components of embodiments discussed above or herein may be combined, and such combinations are encompassed within the scope of the present disclosure. Any specific value discussed above or herein may be combined with another related value discussed above or herein to recite a range with the values representing the upper and lower ends of the range, and such ranges are encompassed within the scope of the present disclosure.

[0197] Other embodiments will become apparent from a review of the ensuing detailed description.BRIEF DESCRIPTION OF THE DRAWINGS

[0198] Figures 1A-1L depict graphs of binding activities of the anti-adeno-associated virus (AAV) antibodies described herein to various adeno-associated virus (AAV) serotypes. RLU, relative light units.

[0199] Figures 2A-2J depict graphs showing immunoglobulin gamma Fc receptor I (FcGR- 1) AAV retargeting by anti-AAV antibodies derived using next-generation sequencing (NGS)Zmass spectrometry (MS) methods (Figures 2A-2F) and by anti-AAV antibodies derived from hybridoma (Figures 2G-2J) described herein for various AAV serotypes.

[0200] Figure 3 shows a schematic representation of alternative format antibody designs for bispecific antibodies of the present disclosure. Exemplary bispecific antibodies target AAV and Asialoglycoprotein Receptor 1 (ASGR1). Star mutations are depicted with an asterisk (*) and knob-in-hole (KiH) mutations are depicted with a triangle (e.g., ◄).

[0201] Figure 4 displays a description of alternative format bispecific antibody molecules described herein.

[0202] Figure 5 illustrates an example rationale for anti-AAV antibody selection.

[0203] Figures 6A-6J depict graphs of binding affinities of alternative format antibodies described herein (e.g., anti-AAV-ASGR1 bispecific antibodies) to an AAV2 heparin bindingmutant (HBM) serotype. The AAV2-HBM serotype contains R585A R588A mutations. RLU, relative light units.

[0204] Figures 7A-7B illustrate that bispecific antibodies can effectively retarget adeno- associated virus (AAV) to the central nervous system (CNS). A schematic representation of anti-transferrin receptor (TfR) x anti-AAV bispecific antibody retargeting of AAV to the CNS is depicted in Figure 7A. A comparison of wild-type (WT) AAV9, covalent-platform control and bispecific platform retargeting of AAV to cerebellum, cortex, and hippocampus is shown in Figure 7B. BBB, blood-brain barrier.

[0205] Figures 8A-8B demonstrate that liver detargeting can be controlled by modulating antibody concentration [Ab] and / or use of a detargeting capsid. A comparison of transduction efficiency between the covalent platform and the bispecific platform evaluated using cDNA quantitation is shown in Figure 8A. A comparison between detargeted AAV9 and WT AA9 using the bispecific platform in cerebellum and liver is shown in Figure 8B. IHC, immunohistochemistry.

[0206] Figure 9 shows a schematic representation of AAV x CACNG1 alternative format (AF) antibodies AF70 and AF71. AF70 comprises anti-AAV#70 scFv fused to the N-terminus of anti-CACNG1 REGN10717 hlgG1 N297G antibody. AF71 comprises anti-AAV#70 scFv fused to the C-terminus of anti-CACNG1 REGN10717 hlgG1 N297G antibody. Disulfide bonds are indicated by S-S.

[0207] Figure 10 shows flow cytometry data illustrating co-incubation of AAV9 W503A with AF70 (top two rows) and AF71 (bottom two rows) resulted in improved transduction efficiency over control AAV without antibody on HEK 293 cells overexpressing mouse CACNG1 (mCACNGI). Transduction efficiency was optimal between molar ratios of 1 AAV to 1 antibody (AAV:Ab ratio 1 :1) and 1 AAV to 9 antibodies (AAV:Ab ratio 1 :9) as assessed by percent (%) GFP positive cells.

[0208] Figure 11 depicts line graphs showing co-incubation of AAV9 W503A with AF70 (top) and AF71 (bottom) resulted in improved transduction efficiency over control AAV without antibody on HEK 293 cells overexpressing mouse CACNG1 (mCACNGI). Transduction efficiency was optimal between molar ratios of 1 AAV to 1 antibody (AAV:Ab ratio 1 :1) and 1 AAV to 9 antibodies (AAV:Ab ratio 1 :9) as assessed by mean fluorescence intensity (MFI).

[0209] Figure 12 shows flow cytometry data illustrating co-incubation of AAV9 W503A with AF70 (top two rows) and AF71 (bottom two rows) resulted in improved AAV transduction efficiency over control AAV without antibody on HEK 293 cells overexpressing human CACNG1 (hCACNGI). Transduction efficiency was optimal between molar ratios of 1 AAV to 1 antibody (AAV:Ab ratio 1 :1) and 1 AAV to 9 antibodies (AAV:Ab ratio 1 :9) as assessed by percent (%) GFP positive cells.

[0210] Figure 13 depicts line graphs showing co-incubation of AAV9 W503A with AF70(top) and AF71 (bottom) resulted in improved AAV transduction efficiency over control AAV without antibody on HEK 293 cells overexpressing human CACNG1 (hCACNGI). Transduction efficiency was optimal between molar ratios of 1 AAV to 1 antibody (AAV:Ab ratio 1 :1) and 1 AAV to 9 antibodies (AAV:Ab ratio 1 :9) as assessed by mean fluorescence intensity (MFI).

[0211] Figure 14 shows immunohistochemical staining of differentiated C2C12 myotubes for Myosin Heavy Chain (MyHC) and demonstration that incubation of AAV with AF70 and AF71 enhanced transduction into the myotubes as determined by GFP fluorescence.

[0212] Figure 15 shows immunohistochemical staining of differentiated human myotubes for Myosin Heavy Chain (MyHC) and demonstration that incubation of AAV with AF70 and AF71 enhanced transduction into the myotubes as determined by GFP fluorescence. Human myotubes were most efficiently transduced with AAV complexed with AF71 at molar ratio 1 :3 and 1 :9.

[0213] Figures 16A-16D demonstrate incubation of AAV with AF70 and AF71 enhanced transduction into differentiated C2C12 myotubes as determined by quantification of GFP positive cells.

[0214] Figures 17A-17D demonstrate incubation of AAV with AF70 and AF71 enhanced transduction into differentiated human myotubes as determined by quantification of GFP positive cells.

[0215] Figures 18A-18B show non-limiting examples of AAVx mTfR alternative format (AF) antibodies described herein. Star mutations are depicted with an asterisk (*) and knob-in-hole (KiH) mutations are depicted with a triangle (e.g., ◄).

[0216] Figure 19 shows an example experimental setup used to test alternative format antibodies binding to AAV9W503A virus by ELISA.

[0217] Figure 20 depicts ELISA data for AAV x mTfR alternative format antibodies binding to AAV9W503A.

[0218] Figure 21 shows a schematic diagram of a FLuc assay protocol used to test retargeting of AAV9W503A using mTfR alternative format antibodies on 293T cells expressing mTfR receptor.

[0219] Figure 22 shows a line graph of data generated in experiments testing AAV9W503A retargeting using AAVxmTfR alternative format antibodies on mTfR293T cells.

[0220] Figures 23A-23C illustrate a retargeting assay using AAV9 scCBH.eGFP.

[0221] Figures 24A-24B show in vitro test infection results for in vivo injection samples.

[0222] Figures 25A-25F depict AAV x mTfR liver and brain (hippocampus, cortex, and cerebellum) green fluorescent protein (GFP) staining for control groups (Figure 25A) and alternative format designs, AAV x mTfR AF1 (Figure 25B), AAV x mTfR AF3 (Figure 25C), AAV x mTfR AF5 (Figure 25D), AAV x mTfR AF7 (Figure 25E), and AAV x mTfR AF9 (Figure25F).

[0223] Figure 26 shows relative RNA expression of GFP in liver samples as determined by RT-qPCR.

[0224] Figure 27 shows RNA expression of GFP in brain samples as determined by RT- qPCR.

[0225] Figures 28A-28D depict GFP staining in brain, heart and liver tissues from mice receiving AAV9 (Figures 28A-28B) or AAV9W503A (Figures 28C and 28D) complexed with AAV x mTfR alternative format AF7 at AAV vector genome (VG) to antibody (Ab) ratios (VG:Ab ratios) of 1 :9 and 1 :3.

[0226] Figures 29A-29I depict AAV x mTfR alternative format designs AF3 and AF7. Figure 29A provides a description of AAV x mTfR alternative format designs AF3 and AF7. Star mutations are depicted with an asterisk (*) and knob-in-hole (KiH) mutations are depicted with a triangle (e.g., ◄). Figures 29B-29E show examples of AAV x mTfR AF3 amino acid sequences (Figure 29B) and corresponding nucleotide sequences (Figures 29C-29E). Figures 29F-29I show examples of AAV x mTfR AF7 amino acid sequences (Figure 29F) and corresponding nucleotide sequences (Figures 29G-29I). Figure discloses “3xG4S” as SEQ ID NO: 1 1 15.

[0227] Figures 30A-30G depict AAV x CACNGI alternative format designs AF70 and AF71. Figure 30A provides a description of AAV x CACNG1 alternative format designs AF70 and AF71. Figures 30B-30G show examples of AAV x mTfR AF70 amino acid sequences (Figure 30B) and corresponding nucleotide sequences (Figures 30C-30D). Figures 30E-30G show examples of AAV x mTfR AF71 amino acid sequences (Figure 30E) and corresponding nucleotide sequences (Figures 30F-30G). Figure discloses “3xG4S” as SEQ ID NO: 1 1 15 and “4xG4S” as SEQ ID NO: 1 161.

[0228] Figure 31 illustrates AAV x CACNG1 bispecific antibody enhancement of transduction into CACNG1 overexpressing 293 cells. GFP expression was assessed by flow cytometry and is shown as % GFP positive cells (top panels) or MFI of GFP expressing cells (bottom panels).

[0229] Figure 32 depicts an example of a study design for testing Hu37 complexed with anti-AAV x CACNG1 2x2 antibodies in D2.MDX mice.

[0230] Figure 33 shows in vitro transduction in HEK293-hCACNG1 of complexes prepared for in vivo study.

[0231] Figures 34A-34C illustrate improved Hu37 transduction in muscle tissues when complexed with an 2x2 anti-CACNG1xAAV alternative format antibody.

[0232] Figures 35A-35B illustrate bispecific antibody enhancement of Hu37 transduction into skeletal muscle.

[0233] Figures 36A-36B depict AAV x ASGR alternative format designs AF21(REGN16199), AF22 (REGN16200), AF29, AF30 (REGN16204), AF32 (REGN16202), AF37, AF41 , AF60A, AF61A, AF62, and AF63. Figure 36A provides a description of AAV x ASGR alternative format designs AF21 (REGN16199), AF22 (REGN16200), AF29, AF30 (REGN16204), and AF32 (REGN16202). Figure 36B provides a description of AAV x ASGR alternative format designs AF37, AF41 , AF60A, AF61A, AF62, and AF63. Figure discloses “3xG4S” as SEQ ID NO: 1115 and “4xG4S” as SEQ ID NO: 1161.

[0234] Figures 37A-37B depict IVIS (In Vivo Imaging Instrument, Perkin Elmer) data illustrating retargeting of AAV to liver with AF30 and AF32.

[0235] Figure 38 depicts IVIS data that demonstrate retargeting of multiple serotypes to liver with AF30.

[0236] Figures 39A-39D depict IVIS & PK qPCR data that demonstrate retargeting to liver with antibodies comprised of either one or two anti-AAV binding arms.

[0237] Figures 40A-40C depict IVIS, PK qPCR, & ELISA data that demonstrate antibody can effectively retarget AAV when dosed prior to AAV administration.

[0238] Figures 41A-41B depict IVIS & PK qPCR data that demonstrate retargeting of REGN16199 with and without Fc.

[0239] Figures 42A-42F depict IVIS, PK qPCR, & RNA Taqman data that demonstrate successful targeting with linear Fab formats.

[0240] Figure 43 depicts PK qPCR data of serum samples 24 hours after administration of various antibody formats complexed with AAV.

[0241] Figure 44 depicts IVIS data that demonstrate retargeting of AAV with a variety of different antibody formats.

[0242] Figure 45 depicts IVIS data that demonstrate retargeting of AAV with antibody comprised of one anti-AAV arm and one anti-ASGR1 arm.

[0243] Figures 46A-46I depict AAV x ASGR alternative format designs AF1 , AF5, and AF9. Figures 46A-46C show examples of AAV x ASGR AF1 amino acid sequences (Figure 46A) and corresponding nucleotide sequences (Figures 46B-46C). Figures 46D-46F show examples of AAV x ASGR AF5 amino acid sequences (Figure 46D) and corresponding nucleotide sequences (Figures 46E-46F). Figures 46G-46I show examples of AAV x ASGR AF9 amino acid sequences (Figure 46G) and corresponding nucleotide sequences (Figures 46H-46I). Figure discloses “3xG4S” as SEQ ID NO: 1115 and “4xG4S” as SEQ ID NO: 1161.

[0244] Figures 47A-47I depict AAV x mTfR alternative format designs AF1 , AF5, and AF9. Figures 47A-47C show examples of AAV x mTfR AF1 amino acid sequences (Figure 47A) and corresponding nucleotide sequences (Figures 47B-47C). Figures 47D-47F show examples of AAV x mTfR AF5 amino acid sequences (Figure 47D) and corresponding nucleotide sequences (Figures 47E-47F). Figures 47G-47I show examples of AAV x mTfR AF9 amino acid sequences (Figure 47G) and corresponding nucleotide sequences (Figures47H-47I). Figure discloses “3xG4S” as SEQ ID NO: 1115 and “4xG4S” as SEQ ID NO: 1161.DETAILED DESCRIPTION

[0245] Before the present disclosure is described, it is to be understood that this disclosure is not limited to particular methods and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

[0246] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. All patents, applications and non-patent publications mentioned in this specification are incorporated herein by reference in their entireties.Definitions

[0247] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. As used herein, the term "about," when used in reference to a particular recited numerical value, means that the value may vary from the recited value by no more than 1%. For example, as used herein, the expression "about 100" includes 99 and 101 and all values in between (e.g., 99.1 , 99.2, 99.3, 99.4, etc.).

[0248] The term “antigen” encompasses any agent (e.g., protein, peptide, polysaccharide, glycoprotein, glycolipid, nucleotide, portions thereof, or combinations thereof) that, when introduced into an immunocompetent host is recognized by the immune system of the host and is capable of eliciting an immune response by the host.

[0249] The term "epitope" can refer to an antigenic determinant that interacts with a specific antigen-binding site in the variable region of an antibody molecule known as a paratope. A single antigen may have more than one epitope. Thus, different antibodies may bind to different areas on an antigen and may have different biological effects. Epitopes may be either conformational or linear. A conformational epitope is produced by spatially juxtaposed amino acids from different segments of the linear polypeptide chain. A linear epitope is one produced by adjacent amino acid residues in a polypeptide chain. In certain circumstance, an epitope may include moieties of saccharides, phosphoryl groups, or sulfonyl groups on the antigen. Epitopes may also be defined as structural or functional. Functional epitopes are generally a subset of structural epitopes and are defined as those residues that directly contribute to the affinity of the interaction between a major histocompatibility complex (MHC) molecule and the antigen.

[0250] The term "antigen-binding molecule" refers in its broadest sense to a molecule that specifically binds to an antigen. In certain embodiments, an antigen-binding molecule is an antibody or an antigen-binding fragment of an antibody, including, e.g., multispecific antibodies such as bispecific antibodies or fragments thereof.

[0251] The term "multispecific antigen-binding molecule" or “multispecific binding molecule” or “MBM” includes molecules (e.g., antibodies and antigen-binding fragments of antibodies) that bind two or more (e.g., three or four) different epitopes or antigens. In some cases, the multispecific antigen-binding molecules are bispecific (e.g., bispecific antibodies). In some cases, the multispecific antigen-binding molecules are trispecific. In some cases, the multispecific antigen-binding molecules are tetraspecific. According to certain exemplary embodiments, the present disclosure includes multispecific (e.g., bispecific) antigen-binding molecules (e.g., antibodies) that specifically bind a capsid of an AAV particle and a molecule of a cell surface. Such antigen-binding molecules may be referred to herein as, e.g., “anti- AAV x anti-cell surface molecule” or other similar terminology (e.g., anti-AAV / anti-cell surface molecule).

[0252] The term “antigen-binding domain” or “ABD” as used herein can refer to the portion of an antigen-binding molecule that is capable of specific binding to an antigen. In certain embodiments, without limitation, a multispecific antigen-binding molecule of the disclosure may comprise a first ABD (“ABD1”), a second ABD (“ABD2”), a third ABD (“ABD3”), and / or a fourth ABD (“ABD4”), each of which may be part of, e.g., an scFv or a Fab.

[0253] The term "antibody", as used herein, means any antigen-binding molecule or molecular complex comprising at least one complementarity determining region (CDR) that specifically binds to or interacts with a particular antigen. The term "antibody" includes immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, as well as multimers thereof (e.g., IgM). The term “antibody” also includes immunoglobulin molecules consisting of four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region comprises three domains, CH1 , CH2 and CH3. Each light chain comprises a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region comprises one domain (CL1). The VHand VLregions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each VHand VLis composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1 , CDR1 , FR2, CDR2, FR3, CDR3, FR4. In different embodiments of the disclosure, the FRs of the anti-AAV antibody oranti-cell surface molecule antibody (or antigen-binding portion thereof) may be identical to the human germline sequences or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.

[0254] The term "antibody", as used herein, also includes antigen-binding fragments of full antibody molecules. The terms "antigen-binding fragment" of an antibody, "antigen-binding portion" of an antibody, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of an antibody may be derived, e.g., from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and optionally constant domains. Such DNA is known and / or is readily available from, e.g., commercial sources, DNA libraries (including, e.g., phage-antibody libraries), or can be synthesized. The DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and / or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, etc.

[0255] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3- CDR3-FR4 peptide. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed within the expression "antigenbinding fragment," as used herein.

[0256] An antigen-binding fragment of an antibody will typically comprise at least one variable domain. The variable domain may be of any size or amino acid composition and will generally comprise at least one CDR which is adjacent to or in frame with one or more framework sequences. In antigen-binding fragments having a VH domain associated with a VLdomain, the VHandLdomains may be situated relative to one another in any suitable arrangement. For example, the variable region may be dimeric and contain VH-VH, VH-VLor L-VL dimers. Alternatively, the antigen-binding fragment of an antibody may contain a monomeric VHor VLdomain.

[0257] In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting, exemplary configurations of variable and constant domains that may be found within an antigen-binding fragment of an antibody of the present disclosure include: (i) VH-CH1 ; (ii) VH- CH2; (iii) VH-CH3; (iv) VH-CH1-CH2; (V) VH-CH1 -CH2-CH3; (vi) VH-CH2-CH3; (vii) VH-CL; (viii) VL- CH1 ; (ix) VL-CH2; (X) VL-CH3; (xi) VL-CH1 -CH2; (xii) VL-CH1 -CH2-CH3; (xiii) VL-CH2-CH3; and (xiv) VL-CL. In any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be either directly linked to one another or may be linked by a full or partial hinge or linker region. A hinge region may consist of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids which result in a flexible or semi-flexible linkage between adjacent variable and / or constant domains in a single polypeptide molecule. Moreover, an antigen-binding fragment of an antibody of the present disclosure may comprise a homo-dimer or hetero-dimer (or other multimer) of any of the variable and constant domain configurations listed above in non- covalent association with one another and / or with one or more monomeric VH or VL domain (e.g., by disulfide bond(s)).

[0258] As with full antibody molecules, antigen-binding fragments may be monospecific or multispecific (e.g., bispecific). A bispecific antigen-binding fragment of an antibody will typically comprise at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Any multispecific antibody format, including the non-limiting example formats disclosed herein, may be adapted for use in the context of an antigen-binding fragment of an antibody of the present disclosure using routine techniques available in the art.

[0259] The terms “complementarity determining region” or “CDR,” as used herein, can refer to the sequences of amino acids within antibody variable regions which confer antigen specificity and binding affinity. In general, there are three CDRs in each heavy chain variable region (HCDR1 , HCDR2, HCDR3) and three CDRs in each light chain variable region (LCDR1 , LCDR2, LCDR3).

[0260] Exemplary conventions that can be used to identify the boundaries of CDRs include, e.g., the Kabat definition, the Chothia definition, the ABS definition and the IMGT definition. See, e.g., Kabat, 1991 , “Sequences of Proteins of Immunological Interest,” National Institutes of Health, Bethesda, Md. (Kabat numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol. 273:927-948 (Chothia numbering scheme); Martin et al., 1989, Proc. Natl. Acad. Sci. USA 86:9268-9272 (ABS numbering scheme); and Lefranc et ai, 2003, Dev. Comp. Immunol. 27:55-77 (IMGT numbering scheme). Public databases are also available for identifying CDR sequences within an antibody.

[0261] The term “single chain Fv” or “scFv” as used herein can refer to a polypeptide chaincomprising the VHand VLdomains of an antibody, where these domains are present in a single polypeptide chain.

[0262] The term “Fab” can refer to a pair of polypeptide chains, the first polypeptide chain comprising a variable heavy (VH) domain of an antibody N- terminal to a first constant domain (referred to herein as C1), and the second polypeptide chain comprising a variable light (VL) domain of an antibody N-terminal to a second constant domain (referred to herein as C2) capable of pairing with the first constant domain. In a native antibody, the VH is N- terminal to the first constant domain (CH1) of the heavy chain and the VLis N- terminal to the constant domain of the light chain (CL). The Fabs of the disclosure can be arranged according to the native orientation or include domain substitutions or swaps on that facilitate correct VH and VL pairings, particularly where the antigen-binding molecules of the disclosure comprise non-identical Fabs. For example, it is possible to replace the CH1 and CL domain pair in a Fab with a CH3-domain pair to facilitate correct modified Fab-chain pairing in heterodimeric antigen-binding molecules. It is also possible to reverse CH1 and CL, so that the CH1 is attached to V_ and CL is attached to the VH, a configuration generally known as Crossmab. Alternatively, or in addition to, the use of substituted or swapped constant domains, correct chain pairing can be achieved by the use of universal light chains that can pair with both variable regions of a heterodimeric antigen-binding molecules of the disclosure.

[0263] The term “universal light chain” as used herein in the context of an antigen-binding molecule described herein can refer to a light chain polypeptide capable of pairing with the heavy chain region of a first Fab to form the first Fab and capable of pairing with the heavy chain region of a second Fab to form the second Fab. Universal light chains are also known as “common light chains.”

[0264] The term “Fc domain” can refer to a portion of the heavy chain that pairs with the corresponding portion of another heavy chain. The term “Fc region” can refer to the region of antibody-based binding molecules formed by association of two heavy chain Fc domains. The two Fc domains within the Fc region may be the same or different from one another. In a native antibody the Fc domains are typically identical, but for the purpose of producing the antigen-binding molecules of the disclosure, one or both Fc domains might advantageously be modified to allow for heterodimerization.

[0265] As used herein, the term “derived from” indicates a relationship between a first and a second molecule. It generally can refer to structural similarity between the first molecule and a second molecule and does not connote or include a process or source limitation on a first molecule that is derived from a second molecule.

[0266] The term “specifically binds” as used herein means that an antigen-binding molecule forms a complex with a target antigen that is relatively stable under physiologicIllconditions. Specific binding can be characterized by a KDof about 5x10-2M or less (e.g., less than 5x10-2M, less than 10-2M, less than 5x102M, less than 10-3M, less than 5x10-4M, less than 10-4M, less than 5x105M, less than 105M, less than 5x10-6M, less than 10-6M, less than 5x107M, less than 107M, less than 5x10-8M, less than 10-8M, less than 5x109M, less than 10'9M, or less than 10-1° M). Methods for determining the binding affinity of an antibody or an antibody fragment, e.g., an antigen-binding molecule or antigen-binding domain, to a target antigen are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance (e.g., Biacore assays), fluorescent-activated cell sorting (FACS) binding assays and the like. An antigen-binding molecule that specifically binds to a target antigen from one species can, however, have cross-reactivity to the target antigen from one or more other species.

[0267] The term “operably linked” as used herein can refer to a functional relationship between two or more regions of a polypeptide chain in which the two or more regions are linked so as to produce a functional polypeptide.

[0268] The term "substantial identity" or "substantially identical," when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 90%, and more preferably at least about 95%, 96%, 97%, 98% or 99% of the nucleotide bases, as mea...

Claims

ClaimsWhat is claimed is:

1. An antibody, or an antigen-binding fragment thereof, wherein said antibody, or said antigen-binding fragment thereof, binds to a capsid of an adeno-associated virus (AAV) particle, and wherein said antibody, or said antigen-binding fragment thereof, comprises: a) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1 159, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1 157; f) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or alight chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or j) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

2. The antibody or antigen-binding fragment of claim 1 , wherein said antibody, or said antigen-binding fragment thereof, comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 8; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 28; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 38; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 48; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3comprising the amino acid sequence of SEQ ID NO: 16; f) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 67; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 87; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 97; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or j) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 107; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

3. The antibody or antigen-binding fragment of claim 2 or 3, wherein said antibody, or said antigen-binding fragment thereof, comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10;e) a HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1 159, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1 157; f) a HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or j) a HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

4. An antibody, or an antigen-binding fragment thereof, wherein said antibody, or said antigen-binding fragment thereof, binds to a capsid of an adeno-associated virus (AAV) particle, wherein said antibody, or said antigen-binding fragment thereof, binds to one or more residues in one or more viral protein 3 (VP3) polypeptides in said capsid, wherein said one or more residues are selected from the residues listed in Tables 18- 26.

5. The antibody or antigen-binding fragment of claim 4, wherein said antibody, or said antigen-binding fragment thereof, binds to a capsid of an AAV2 particle comprising amino acid substitutions R585A and R588A, and wherein the said one or more residues are selected from the following residues in said VP3 polypeptides (according to VP1 numbering): a) S264, A266, N268, H271 , N382, S384, Q385, G512, R487, D494, K527, D529, K532, L538, D533, E555, N705, K706, V708, T450, Q457, and R459; b) S264, G265, A266, S267, N268, H271 , N382, G383, S384, R487, K527, D528, E530, E574, Q575, K706, and S707; c) N254, L256, K258, I260, S261 , Q263, Y272, E322, V323, T324, Q325, A655, A667, S668, F669, I670, T671 , I332, Q545, G546, S547, E548, K556, N717, V719, T660, and F661 ; and / or d) N254, L256, Q263, S264, V323, T324, Q325, S655, A667, S668, F669, I670, T671 , G328, G546, E548, T716, and N717.

6. The antibody or antigen-binding fragment of claim 4, wherein said antibody, or said antigen-binding fragment thereof, binds to a capsid of an AAV8 particle, and wherein the said one or more residues are selected from the following residues in said VP3polypeptides (according to VP1 numbering): a) N255, L257, K259, 1261 , S262, N263, S266, A269, Y275, E325, V326, T327, Q328, A658, N670, S671 , F672, I673, T674, Q548, N549, A550, A551, D559, E720, and T663; and / or b) N255, L257, S266, E325, V326, T327, Q328, N670, S671, F672, I673, T674, N549, T719, and E720.

7. The antibody or antigen-binding fragment of claim 4, wherein said antibody, or said antigen-binding fragment thereof, binds to a capsid of an AAV9 particle, and wherein the said one or more residues are selected from the following residues in said VP3 polypeptides (according to VP1 numbering): a) N254, I260, N262, Y274, E324, V325, T326, D327, N328, R550, D665, N668, S669, F670, 1671 , T672, Q546, G547, G549, E718, and A661 ; and / or b) N254, L256, I260, N262, E324, V325, T326, D551 , N668, S669, F670, T672, G330, and E718.

8. The antibody or antigen-binding fragment of any one of claims 4-7, wherein said antibody, or said antigen-binding fragment thereof, comprises:1) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10;2) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157;3) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or4) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

9. The antibody or antigen-binding fragment of claim 8, wherein said antibody, or said antigen-binding fragment thereof, comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprisingthe amino acid sequence of SEQ ID NO: 36, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 38; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 87; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

10. The antibody or antigen-binding fragment of claim 8 or 9, wherein said antibody, or said antigen-binding fragment thereof, comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or4) a HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

11. The antibody or antigen-binding fragment of any one of claims 1-10, wherein said antibody, or said antigen-binding fragment thereof, is a humanized antibody or antigen binding fragment thereof, human antibody or antigen binding fragment thereof, murine antibody or antigen binding fragment thereof, chimeric antibody or antigen binding fragment thereof, Fab fragment, F(ab')2 fragment, F(ab)'3 fragments, single-chain fragment variable (scFv), bis-scFv, (scFv)2, diabody, minibody, nanobody, triabody,tetrabody, disulfide stabilized Fv protein (dsFv), single-domain antibody (sdAb), Ig NAR, single heavy chain antibody, bispecific antibody, trispecific antibody, or chemically modified derivative thereof. The antibody or antigen-binding fragment of any one of claims 1-11 , wherein said antibody, or said antigen-binding fragment thereof, comprises an lgG1 , lgG2, lgG3, or lgG4 constant region, or a variant thereof. The antibody or antigen-binding fragment of claim 12, wherein said antibody, or said antigen-binding fragment thereof, comprises an lgG1 constant region, or a variant thereof. The antibody or antigen-binding fragment of claim 13, wherein the lgG1 constant region comprises the amino acid sequence of SEQ ID NO: 259 or 1164. The antibody or antigen-binding fragment of claim 12, wherein said antibody, or said antigen-binding fragment thereof, comprises an lgG4 constant region, or a variant thereof. The antibody or antigen-binding fragment of claim 15, wherein the lgG4 variant comprises a hinge domain modified to reduce binding to Fey receptors. The antibody or antigen-binding fragment of claim 16, wherein the lgG4 constant region comprises the amino acid sequence of SEQ ID NO:

261. The antibody or antigen-binding fragment of any one of claims 1-11 , wherein said antigen-binding fragment is a Fab fragment. The antibody or antigen-binding fragment of any one of claims 1-11 , wherein said antigen-binding fragment is an scFv fragment. The antibody or antigen-binding fragment of any one of claims 1-19, wherein said antibody, or said antigen-binding fragment thereof, binds to AAV2 with a dissociation constant (KD) of less than about 1.5 x 10‘6M, as measured in a surface plasmon resonance assay. The antibody or antigen-binding fragment of claim 20, wherein said antibody, or saidantigen-binding fragment thereof, binds to AAV2 with a dissociation constant (KD) of less than about 20 nM, as measured in a surface plasmon resonance assay.

22. The antibody or antigen-binding fragment of any one of claims 1-21 , wherein said capsid comprises one or more wild-type AAV capsid polypeptides.

23. The antibody or antigen-binding fragment of any one of claims 1-21 , wherein said capsid comprises one or more non-wild-type AAV capsid polypeptides.

24. The antibody or antigen-binding fragment of any one of claims 1-23, wherein binding of said antibody or antigen-binding fragment thereof to said AAV particle capsid does not neutralize said AAV particle.

25. An antibody, or an antigen-binding fragment thereof, that binds to the same epitope as the antibody or antigen-binding fragment of any one of claims 1-24.

26. An antibody, or an antigen-binding fragment thereof, that competes for binding to a capsid of an adeno-associated virus (AAV) particle with the antibody or antigen-binding fragment of any one of claims 1 -24.

27. A pharmaceutical composition comprising the antibody or antigen-binding fragment of any one of claims 1-26 and a pharmaceutically acceptable carrier or excipient.

28. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: i) a first antigen-binding domain that binds to a capsid of an adeno-associated virus (AAV) particle; and ii) a second antigen-binding arm that binds to a molecule on a cell surface, wherein said first antigen-binding domain comprises: a) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10;c) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; f) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or j) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

29. The multispecific antibody or multispecific antigen-binding fragment of claim 28, wherein said first antigen-binding domain comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and a HCDR3 comprising the amino acidsequence of SEQ ID NO: 8; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 28; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 38; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 48; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 67; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 87; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3comprising the amino acid sequence of SEQ ID NO: 16; i) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 97; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or j) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 107; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

30. The multispecific antibody or multispecific antigen-binding fragment of claim 28 or 29, wherein said first antigen-binding domain comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; f) a HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or j) a HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

31. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising:i) a first antigen-binding domain that binds to a capsid of an adeno-associated virus (AAV) particle, and ii) a second antigen-binding domain that binds to a molecule on a cell surface, wherein said first antigen-binding domain binds to one or more residues in one or more viral protein 3 (VP3) polypeptides in said capsid, wherein said one or more residues are selected from the residues listed in Tables 18-26.

32. The multispecific antibody or multispecific antigen-binding fragment of claim 31 , wherein said first antigen-binding domain binds to a capsid of an AAV2 particle comprising amino acid substitutions R585A and R588A, and wherein the said one or more residues are selected from the following residues in said VP3 polypeptides (according to VP1 numbering): a) S264, A266, N268, H271 , N382, S384, Q385, G512, R487, D494, K527, K529, K532, L538, D533, E555, N705, K706, V708, T450, Q457, and R459; b) S264, G265, A266, S267, N268, H271 , N382, G383, S384, R487, K527, D528, E530, Q574, Q575, K706, and S707; c) N254, L256, K258, I260, S261 , Q263, Y272, E322, V323, T324, Q325, A655, A667, S668, F669, I670, T671 , I332, Q545, G546, S547, E548, K556, N717, V719, T660, and F661 ; and / or d) N254, L256, Q263, S264, V323, T324, Q325, S655, A667, S668, F669, I670, T671 , G328, G546, E548, T716, and N717.

33. The multispecific antibody or multispecific antigen-binding fragment of claim 31 , wherein said first antigen-binding domain binds to a capsid of an AAV8 particle, and wherein the said one or more residues are selected from the following residues in said VP3 polypeptides (according to VP1 numbering): e) N255, L257, K259, 1261 , S262, N263, S266, A269, Y275, E325, V326, T327, Q328, A658, N670, S671 , F672, I673, T674, Q548, N549, A550, A551 , D559, E720, and T663; and / or f) N255, L257, S266, E325, V326, T327, Q328, N670, S671 , F672, I673, T674, N549, T719, and E720.

34. The multispecific antibody or multispecific antigen-binding fragment of claim 31 , wherein said first antigen-binding domain binds to a capsid of an AAV9 particle, and wherein the said one or more residues are selected from the following residues in said VP3 polypeptides (according to VP1 numbering): g) N254, I260, N262, Y274, E324, V325, T326, D327, N328, R550, D665, N668, S669, F670, 1671 , T672, Q546, G547, G549, E718, and A661 ; and / or h) N254, L256, I260, N262, E324, V325, T326, D551 , N668, S669, F670, T672, G330, andE718.

35. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 31-34, wherein the first antigen-binding domain comprises:1) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10;2) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157;3) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or4) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

36. The multispecific antibody or multispecific antigen-binding fragment of claim 35, wherein the first antigen-binding domain comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 38; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3comprising the amino acid sequence of SEQ ID NO: 16; or4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 87; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

37. The multispecific antibody or multispecific antigen-binding fragment of claim 35 or 36, wherein the first antigen-binding domain comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; or4) a HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

38. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28-37, wherein said molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel auxiliary subunit gamma 1 (CACNG1).

39. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28-38, wherein said molecule on the cell surface is ASGR1 .

40. The multispecific antibody or multispecific antigen-binding fragment of claim 39, wherein said second antigen-binding domain that binds to ASGR1 comprises: a) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; or b) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.41 . The multispecific antibody or multispecific antigen-binding fragment of claim 39 or 40, wherein said second antigen-binding domain that binds to ASGR1 comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 226; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 236; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

42. The multispecific antibody or multispecific antigen-binding fragment thereof of any one of claims 39-41 , wherein said second antigen-binding domain that binds to ASGR1 comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1 157; or b) a HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

43. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28-38, wherein said molecule on the cell surface is TfR.

44. The multispecific antibody or multispecific antigen-binding fragment of claim 43, wherein said second antigen-binding domain that binds to TfR comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid nusequence of SEQ ID NO: 298;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 319 or 320;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 377;1 1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVRcomprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 51 1 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR that comprisesthe LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599;32) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

45. The multispecific antibody or multispecific antigen-binding fragment of claim 43 or 44, wherein said second antigen-binding domain that binds to TfR comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 274; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 279;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 285; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 290;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 296; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 301 ;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 306; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 311 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 312;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 317; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 321, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and a LCDR3comprising the amino acid sequence of SEQ ID NO: 323;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 329; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 335;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 341 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 347;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 351 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 353; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 359;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 364; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 369;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 375; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 380;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 385; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 390;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 396; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 401 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 402;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, a HCDR2 comprisingthe amino acid sequence of SEQ ID NO: 406, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 407; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 411 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 412;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 417; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 421 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 422;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 428; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 434;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 439; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 444;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 450; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 455;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 460; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 465;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 471 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 477;20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 481 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 483; and / or a LCDR1 comprising the amino acid sequence of SEQID NO: 486, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 488;21) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 494; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 499;22) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 503, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 504; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 509;23) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 514; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 519;24) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 524; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 529;25) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 534; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 539;26) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 545; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 550;27) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 555; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 560;28) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 565; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 570;29) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 575; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 578, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 580;30) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 585; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 590;31) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 596; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 601 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 602;32) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 607; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 61 1 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 613; or33) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 121 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1 123, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1 125; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1 129, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1131 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1133.

46. The multispecific antibody or multispecific antigen-binding fragment thereof of any one of claims 43-45, wherein said second antigen-binding domain that binds to TfR comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 319 or 320;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 377;11) a HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR comprising the amino acid sequence of SEQ ID NO: 511 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599;32) a HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

47. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28-38, wherein said molecule on the cell surface is CACNG1.

48. The multispecific antibody or multispecific antigen-binding fragment of claim 47, wherein said second antigen-binding domain that binds to CACNG1 comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVRcomprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 803;11) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR that comprises theLCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequenceof SEQ ID NO: 1213.

49. The multispecific antibody or multispecific antigen-binding fragment of claim 47 or 48, wherein said second antigen-binding domain that binds to CACNG1 comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 621 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 629;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 641 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 649;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 661 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 669;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 681 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 689;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 701 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 709;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 721 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 729;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 741 ; and / or a LCDR1 comprising the amino acid sequence of SEQID NO: 745, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 749;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 761 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 769;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 781 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 789;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 801 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 809;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 821 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 829;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 841 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 849;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 861 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 869;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 881 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 889;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 901 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 909;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 921 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 929;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 941 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 949;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 961 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 969;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 183, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1 185, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1 187; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1 191 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1193, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195; or20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1207, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1209, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 121 1 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1215, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1217, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1219.

50. The multispecific antibody or multispecific antigen-binding fragment thereof of any one of claims 47-49, wherein said second antigen-binding domain that binds to CACNG1 comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 803;11) a HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 1181 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or20) a HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

51. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1 ”) operably linked to (ii) a second heavy chain region of a second Fab (“Fab2”); b) a second polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a first antigen-binding domain (“ABD1 ”); and c) a third polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain (“ABD2”); wherein ABD1 or ABD2 binds to a capsid of an adeno-associated virus (AAV) particle, and the other of ABD1 or ABD2 binds to a molecule on a cell surface.

52. The multispecific antibody or multispecific antigen-binding fragment of claim 51 , wherein ABD1 binds to a capsid of an adeno-associated virus (AAV) particle and ABD2 binds to a molecule on the cell surface.

53. The multispecific antibody or multispecific antigen-binding fragment of claim 51 , wherein ABD2 binds to a capsid of an adeno-associated virus (AAV) particle and ABD1 binds to a molecule on the cell surface.

54. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 51-53, wherein the first heavy chain region is linked to the second heavy chain region via a linker.

55. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first scFv comprising a first antigen-binding domain (“ABD1”) operably linked to (ii) an Fc domain; b) a second polypeptide chain, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1 ”) operably linked to (ii) an Fc domain; and c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a second antigen-binding domain (“ABD2”); wherein ABD1 or ABD2 binds to a capsid of an adeno-associated virus (AAV) particle, and the other of ABD1 or ABD2 binds to a molecule on a cell surface.

56. The multispecific antibody or multispecific antigen-binding fragment of claim 55,wherein ABD1 binds to a capsid of an adeno-associated virus (AAV) particle and ABD2 binds to a molecule on the cell surface.

57. The multispecific antibody or multispecific antigen-binding fragment of claim 55, wherein ABD2 binds to a capsid of an adeno-associated virus (AAV) particle and ABD1 binds to a molecule on the cell surface.

58. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 55-57, wherein the first scFv and / or the first heavy chain region is linked to the Fc domain via a linker.

59. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 51-58, wherein the ABD1 or ABD2 which binds to a capsid of an AAV particle comprises: a) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1 159, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1 157; f) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 containedwithin a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; and / or j) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

60. The multispecific antibody or multispecific antigen-binding fragment of claim 59, wherein the ABD1 or ABD2 which binds to a capsid of an AAV particle comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 8; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 28; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 38; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and a HCDR3 comprising the amino acidsequence of SEQ ID NO: 48; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 67; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 87; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 97; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; and / or j) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 107; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.61 . The multispecific antibody or multispecific antigen-binding fragment of claim 59 or 60, wherein the ABD1 or ABD2 which binds to a capsid of an AAV particle comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 10; b) a HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1 159, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1 157; f) a HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; and / or j) a HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

62. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 51-61 , wherein said molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel auxiliary subunit gamma 1 (CACNG1).

63. The multispecific antibody or multispecific antigen-binding fragment of claim 62, wherein said molecule on the cell surface is ASGR1 .

64. The multispecific antibody or multispecific antigen-binding fragment of claim 63, wherein the other of ABD1 or ABD2 which binds to ASGR1 comprises: a) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; or b) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequenceof SEQ ID NO: 10.

65. The multispecific antibody or multispecific antigen-binding fragment of claim 63 or 64, wherein the other of ABD1 or ABD2 which binds to ASGR1 comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 226; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 236; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

66. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 63-65, wherein the other of ABD1 or ABD2 which binds to ASGR1 comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1 157; or b) a HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

67. The multispecific antibody or multispecific antigen-binding fragment of claim 62, wherein said molecule on the cell surface is TfR.

68. The multispecific antibody or multispecific antigen-binding fragment of claim 67, wherein the other of ABD1 or ABD2 which binds to TfR comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR that comprisesthe LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 319 or 320;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 377;1 1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acidsequence of SEQ ID NO: 398 or 399;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 51 1 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVRcomprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599;32) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1 119, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

69. The multispecific antibody or multispecific antigen-binding fragment of claim 67 or 68, wherein the other of ABD1 or ABD2 which binds to TfR comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 274; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 279;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 285; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 290;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 296; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 301 ;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 306; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 31 1 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 312;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 317; and / or a LCDR1 comprising the amino acid sequence of SEQID NO: 321, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 323;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 329; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 335;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 341 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 347;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 351 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 353; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 359;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 364; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 369;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 375; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 380;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 385; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 390;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 396; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 401 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 402;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 407; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 411 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 412;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 417; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 421 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 422;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 428; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 434;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 439; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 444;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 450; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 455;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 460; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 465;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 471 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 477;20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 481 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and a HCDR3 comprising the amino acidsequence of SEQ ID NO: 483; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 488;21) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 494; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 499;22) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 503, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 504; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 509;23) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 514; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 519;24) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 524; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 529;25) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 534; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 539;26) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 545; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 550;27) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 555; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and a LCDR3comprising the amino acid sequence of SEQ ID NO: 560;28) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 565; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 570;29) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 575; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 578, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 580;30) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 585; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 590;31) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 596; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 601 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 602;32) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 607; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 61 1 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 613; or33) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 121 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1 123, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1 125; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1 129, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1131 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1133.

70. The multispecific antibody or multispecific antigen-binding fragment thereof of any one of claims 67-69, wherein the other of ABD1 or ABD2 which binds to TfR comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 319 or 320;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 377;11) a HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR comprising the amino acid sequence of SEQ ID NO: 511 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599 ;32) a HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

71. The multispecific antibody or multispecific antigen-binding fragment of claim 62, wherein said molecule on the cell surface is CACNG1.

72. The multispecific antibody or multispecific antigen-binding fragment of claim 71 , wherein the other of ABD1 or ABD2 which binds to CACNG1 comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVRcomprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 803;11) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR that comprises theLCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequenceof SEQ ID NO: 1213.

73. The multispecific antibody or multispecific antigen-binding fragment of claim 71 or 72, wherein the other of ABD1 or ABD2 which binds to CACNG1 comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 621 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 629;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 641 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 649;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 661 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 669;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 681 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 689;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 701 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 709;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 721 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 729;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 741 ; and / or a LCDR1 comprising the amino acid sequence of SEQID NO: 745, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 749;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 761 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 769;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 781 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 789;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 801 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 809;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 821 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 829;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 841 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 849;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 861 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 869;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 881 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 889;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 901 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 909;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 921 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 929;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 941 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 949;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 961 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 969;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 183, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1 185, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1 187; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1 191 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1193, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195; or20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1207, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1209, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 121 1 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1215, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1217, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1219.

74. The multispecific antibody or multispecific antigen-binding fragment thereof of any one of claims 71-73, wherein the other of ABD1 or ABD2 which binds to CACNG1 comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 803;11) a HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 1181 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or20) a HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

75. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) an scFv comprising a first antigen-binding domain (“ABDI”) operably linked to (ii) a first heavy chain region of a first Fab (Tab1”), said first heavy chain region operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a second heavy chain region of a second Fab (Tab2”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a second antigen-binding domain (“ABD2”); and d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain (“ABD3”); wherein at least one of ABD1 , ABD2, and ABD3 binds to a capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1 , ABD2 and ABD3 bind to a molecule on a cell surface.

76. The multispecific antibody or multispecific antigen-binding fragment of claim 75, wherein two of ABD1 , ABD2 and ABD3 bind to a capsid of an AAV particle, and one of ABD1 , ABD2 and ABD3 binds to a molecule on a cell surface.

77. The multispecific antibody or multispecific antigen-binding fragment of claim 76, wherein ABD2 and ABD3 bind to a capsid of an AAV particle, and ABD1 binds to a molecule on a cell surface.

78. The multispecific antibody or multispecific antigen-binding fragment of claim 76, wherein ABD1 and ABD3 bind to a capsid of an AAV particle, and ABD2 binds to a molecule on a cell surface.

79. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 43-78, wherein the scFv is linked to the first heavy chain region via a linker.

80. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1”) operably linked to (ii) an Fc domain, said Fc domain operably linked to (iii) an scFv comprising a first antigen-binding domain (“ABD1”); b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a secondheavy chain region of a second Fab (“Fab2”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a second antigen-binding domain (“ABD2”); and d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain (“ABD3”); wherein at least one of ABD1 , ABD2 and ABD3 binds to a capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1 , ABD2 and ABD3 bind to a molecule on a cell surface.

81. The multispecific antibody or multispecific antigen-binding fragment of claim 80, wherein two of ABD1 , ABD2 and ABD3 bind to a capsid of an AAV particle, and one of ABD1 , ABD2 and ABD3 binds to a molecule on a cell surface.

82. The multispecific antibody or multispecific antigen-binding fragment of claim 81 , wherein ABD2 and ABD3 bind to a capsid of an AAV particle, and ABD1 binds to a molecule on a cell surface.

83. The multispecific antibody or multispecific antigen-binding fragment of claim 81 , wherein ABD1 and ABD2 bind to a capsid of an AAV particle, and ABD3 binds to a molecule on a cell surface.

84. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 80-83, wherein the scFv is linked to the Fc domain via a linker.

85. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1 ”) operably linked to (ii) a second heavy chain region of a second Fab (“Fab2”), said second heavy chain region of Fab2 operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a third heavy chain region of a third Fab (Tab3”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a first antigen-binding domain (“ABD1 ”); d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain (“ABD2”); and e) a fifth polypeptide chain comprising a third light chain that pairs with the third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain (“ABD3”);wherein at least one of ABD1 , ABD2 and ABD3 binds to a capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1 , ABD2 and ABD3 bind to a molecule on a cell surface.

86. The multispecific antibody or multispecific antigen-binding fragment of claim 85, wherein two of ABD1 , ABD2 and ABD3 bind to a capsid of an AAV particle, and one of ABD1 , ABD2 and ABD3 binds to a molecule on a cell surface.

87. The multispecific antibody or multispecific antigen-binding fragment of claim 86, wherein ABD2 and ABD3 bind to a capsid of an AAV particle, and ABD1 binds to a molecule on a cell surface.

88. The multispecific antibody or multispecific antigen-binding fragment of claim 86, wherein ABD1 and ABD3 bind to a capsid of an AAV particle, and ABD2 binds to a molecule on a cell surface.

89. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 85-88, wherein the first heavy chain region is linked to the second heavy chain region via a linker.

90. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1 ”) operably linked to (ii) an Fc domain, said Fc domain operably linked to (iii) a second heavy chain region of a second Fab (“Fab2”); b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a third heavy chain region of a third Fab (“Fab3”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a first antigen-binding domain (“ABD1 ”); d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain (“ABD2”); and e) a fifth polypeptide chain comprising a third light chain that pairs with the third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain (“ABD3”); wherein at least one of ABD1 , ABD2 and ABD3 binds to a capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1 , ABD2 and ABD3 bind to a molecule on a cell surface.

91. The multispecific antibody or multispecific antigen-binding fragment of claim 90,wherein two of ABD1 , ABD2 and ABD3 bind to a capsid of an AAV particle, and one of ABD1 , ABD2 and ABD3 binds to a molecule on a cell surface.

92. The multispecific antibody or multispecific antigen-binding fragment of claim 91 , wherein ABD1 and ABD3 bind to a capsid of an AAV particle, and ABD2 binds to a molecule on a cell surface.

93. The multispecific antibody or multispecific antigen-binding fragment of claim 91 , wherein ABD1 and ABD2 bind to a capsid of an AAV particle, and ABD3 binds to a molecule on a cell surface.

94. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 90-93, wherein the second heavy chain region is linked to the Fc domain via a linker.

95. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1 ”) operably linked to (ii) an scFv comprising a first antigen-binding domain (“ABD1 ”), said scFv operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a second heavy chain region of a second Fab (“Fab2”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a second antigen-binding domain (“ABD2”); and d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain (“ABD3”); wherein at least one of ABD1 , ABD2 and ABD3 binds to a capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1 , ABD2 and ABD3 bind to a molecule on a cell surface.

96. The multispecific antibody or multispecific antigen-binding fragment of claim 95, wherein two of ABD1 , ABD2 and ABD3 bind to a capsid of an AAV particle, and one of ABD1 , ABD2 and ABD3 binds to a molecule on a cell surface.

97. The multispecific antibody or multispecific antigen-binding fragment of claim 96, wherein ABD2 and ABD3 bind to a capsid of an AAV particle, and ABD1 binds to a molecule on a cell surface.. The multispecific antibody or multispecific antigen-binding fragment of claim 96, wherein ABD1 and ABD2 bind to a capsid of an AAV particle, and ABD3 binds to a molecule on a cell surface. . The multispecific antibody or multispecific antigen-binding fragment of any one of claims 95-98, wherein the scFv is linked to the first heavy chain region via a linker.

0. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1”) operably linked to (ii) an Fc domain, said Fc domain operably linked to (iii) a second heavy chain region of a second Fab (“Fab2”); b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) an scFv comprising a first antigen-binding domain (“ABD1”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a second antigen-binding domain (“ABD2”); and d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain (“ABD3”); wherein at least one of ABD 1 , ABD2 and ABD3 binds to a capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1 , ABD2 and ABD3 bind to a molecule on a cell surface.

1. The multispecific antibody or multispecific antigen-binding fragment of claim 100, wherein two of ABD1 , ABD2 and ABD3 bind to a capsid of an AAV particle, and one of ABD1 , ABD2 and ABD3 binds to a molecule on a cell surface.

2. The multispecific antibody or multispecific antigen-binding fragment of claim 101 , wherein ABD2 and ABD3 bind to a capsid of an AAV particle, and ABD1 binds to a molecule on a cell surface.

3. The multispecific antibody or multispecific antigen-binding fragment of claim 101 , wherein ABD1 and ABD2 bind to a capsid of an AAV particle, and ABD3 binds to a molecule on a cell surface.

4. The multispecific antibody or multispecific antigen-binding fragment of any one ofclaims 100-103, wherein the second heavy chain region is linked to the Fc domain via a linker.

105. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1 ”) operably linked to (ii) a second heavy chain region of a second Fab (“Fab2”), said second heavy chain region operably linked to (iii) a third heavy chain region of a third Fab (“Fab3”); b) a second polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a first antigen-binding domain (“ABD1 ”); and c) a third polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain (“ABD2”); d) a fourth polypeptide chain comprising a third light chain that pairs with the third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain (“ABD3”); wherein at least one of ABD1 , ABD2, and ABD3 binds to a capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1 , ABD2 and ABD3 bind to a molecule on a cell surface.

106. The multispecific antibody or multispecific antigen-binding fragment of claim 105, wherein two of ABD1 , ABD2 and ABD3 bind to a capsid of an AAV particle, and one of ABD1 , ABD2 and ABD3 binds to a molecule on a cell surface.

107. The multispecific antibody or multispecific antigen-binding fragment of claim 106, wherein ABD2 and ABD3 bind to a capsid of an AAV particle, and ABD1 binds to a molecule on a cell surface.

108. The multispecific antibody or multispecific antigen-binding fragment of claim 106, wherein ABD1 and ABD3 bind to a capsid of an AAV particle, and ABD2 binds to a molecule on a cell surface.

109. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 105-108, wherein the first heavy chain region is operably linked to the second heavy chain region and / or the second heavy chain region is operably linked to the third heavy chain region via a linker.1 10. The multispecific antibody or multispecific antigen-binding fragment of any one ofclaims 75-109, wherein the at least one of ABD1 , ABD2 and ABD3 which binds to a capsid of an AAV particle comprises: a) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; f) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 containedwithin a LCVR comprising the amino acid sequence of SEQ ID NO: 10; and / or j) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

111. The multispecific antibody or multispecific antigen-binding fragment of claim 110, wherein the at least one of ABD1 , ABD2 and ABD3 which binds to a capsid of an AAV particle comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 8; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 28; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 38; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 48; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 67; and / or a LCDR1 comprising the amino acid sequence of SEQID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 87; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 97; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; and / or j) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 107; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

112. The multispecific antibody or multispecific antigen-binding fragment of claim 110 or 111 , wherein the at least one of ABD1 , ABD2 and ABD3 which binds to a capsid of an AAV particle comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; f) a HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 10; g) a HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; and / or j) a HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.1 13. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 75-112, wherein said molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel auxiliary subunit gamma 1 (CACNG1).1 14. The multispecific antibody or multispecific antigen-binding fragment of claim 113, wherein said molecule on the cell surface is ASGR1 .1 15. The multispecific antibody or multispecific antigen-binding fragment of claim 114, wherein the other(s) of ABD1 , ABD2 and ABD3 which binds to ASGR1 comprises: a) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; or b) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.1 16. The multispecific antibody or multispecific antigen-binding fragment of claim 114 or1 15, wherein the other(s) of ABD1 , ABD2 and ABD3 which binds to ASGR1 comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 226; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, a HCDR2 comprisingthe amino acid sequence of SEQ ID NO: 234, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 236; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.1 17. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 1 14-1 16, wherein the other(s) of ABD1 , ABD2 and ABD3 which binds to ASGR1 comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1 157; or b) a HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.1 18. The multispecific antibody or multispecific antigen-binding fragment of claim 113, wherein said molecule on the cell surface is TfR.1 19. The multispecific antibody or multispecific antigen-binding fragment of claim 118, wherein the other(s) of ABD1 , ABD2 and ABD3 which binds to TfR comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequenceof SEQ ID NO: 319 or 320;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 377;1 1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 51 1 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVRcomprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599;32) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1 119, and / or a LCVR that comprises theLCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

120. The multispecific antibody or multispecific antigen-binding fragment of claim 118 or 119, wherein the other(s) of ABD 1 , ABD2 and ABD3 which binds to TfR comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 274; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 279;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 285; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 290;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 296; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 301 ;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 306; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 311 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 312;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 317; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 321, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 323;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 329; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 335;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and a HCDR3 comprising the amino acidsequence of SEQ ID NO: 341 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 347;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 351 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 353; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 359;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 364; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 369;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 375; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 380;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 385; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 390;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 396; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 401 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 402;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 407; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 411 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 412;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 417; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 421 , and a LCDR3comprising the amino acid sequence of SEQ ID NO: 422;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 428; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 434;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 439; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 444;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 450; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 455;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 460; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 465;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 471 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 477;20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 481 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 483; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 488;21) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 494; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 499;22) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, a HCDR2 comprisingthe amino acid sequence of SEQ ID NO: 503, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 504; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 509;23) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 514; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 519;24) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 524; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 529;25) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 534; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 539;26) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 545; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 550;27) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 555; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 560;28) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 565; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 570;29) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 575; and / or a LCDR1 comprising the amino acid sequence of SEQID NO: 578, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 580;30) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 585; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 590;31) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 596; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 601 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 602;32) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 607; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 61 1 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 613; or33) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 121 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1 123, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1 125; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1 129, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1131 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1133.

121. The multispecific antibody or multispecific antigen-binding fragment thereof of any one of claims 1 18-120, wherein the other(s) of ABD1 , ABD2 and ABD3 which binds to TfR comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 319 or 320;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 377;11) a HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR comprising the amino acid sequence of SEQ ID NO: 511 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599 ;32) a HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

122. The multispecific antibody or multispecific antigen-binding fragment of claim 113, wherein said molecule on the cell surface is CACNG1.

123. The multispecific antibody or multispecific antigen-binding fragment of claim 122, wherein the other(s) of ABD1 , ABD2 and ABD3 which binds to CACNG1 comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVRcomprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 803;11) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR that comprises theLCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

124. The multispecific antibody or multispecific antigen-binding fragment of claim 122 or 123, wherein the other(s) of ABD1 , ABD2 and ABD3 which binds to CACNG1 comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 621 ; and / or a LCDR1 comprising the amino acid sequence of SEQID NO: 625, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 629;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 641 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 649;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 661 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 669;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 681 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 689;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 701 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 709;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 721 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 729;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 741 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 745, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 749;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 761 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 769;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 781 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 789;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 801 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 809;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 821 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 829;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 841 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 849;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 861 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 869;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 881 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 889;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 901 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 909;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and a HCDR3 comprising the amino acidsequence of SEQ ID NO: 921 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 929;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 941 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 949;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 961 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 969;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 183, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1 185, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1 187; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1 191 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1193, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195; or20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1207, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1209, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 121 1 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1215, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1217, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1219.

125. The multispecific antibody or multispecific antigen-binding fragment thereof of any one of claims 122-124, wherein the other(s) of ABD1 , ABD2 and ABD3 which binds toCACNG1 comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 803;11) a HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 1181 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or20) a HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

126. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first scFv comprising a first antigen-binding domain (“ABD1”) operably linked to (ii) a first heavy chain region of a first Fab (“Fab1”), said first heavy chain region of Fab1 operably linked to (iii) an Fc domain;b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a second scFv comprising a second antigen-binding domain (“ABD2”) operably linked to (ii) a second heavy chain region of a second Fab (“Fab2”), said second heavy chain region of Fab2 operably linked to (iii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a third antigen-binding domain (“ABD3”); and d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a fourth antigen-binding domain (“ABD4”); wherein at least one of ABD1 , ABD2, ABD3 and ABD4 binds to a capsid of an adeno- associated virus (AAV) particle, and the other(s) of ABD1 , ABD2, ABD3, and ABD4 bind to a molecule on a cell surface.

127. The multispecific antibody or multispecific antigen-binding fragment of claim 126, wherein two of ABD1 , ABD2, ABD3, and ABD4 bind to a capsid of an AAV particle, and two of ABD1 , ABD2, ABD3 and ABD4 binds to a molecule on a cell surface.

128. The multispecific antibody or multispecific antigen-binding fragment of claim 127, wherein ABD1 and ABD2 bind to a capsid of an AAV particle, and ABD3 and ABD4 binds to a molecule on a cell surface.

129. The multispecific antibody or multispecific antigen-binding fragment of claim 127, wherein ABD3 and ABD4 bind to a capsid of an AAV particle, and ABD1 and ABD2 binds to a molecule on a cell surface.

130. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 126-129, wherein the first scFv is linked to the first heavy chain region and / or the second scFv is linked to the second heavy chain region via a linker.

131. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1 ”) operably linked to (ii) an Fc domain, said Fc domain operably linked to (iii) a first scFv comprising a first antigen-binding domain (“ABD1 ”); b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a second heavy chain region of a second Fab (“Fab2”) operably linked to (ii) an Fc domain, said Fc domain operably linked to (iii) a second scFv comprising a second antigen-binding domain (“ABD2”);c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a third antigen-binding domain (“ABD3”); and d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a fourth antigen-binding domain (“ABD4”); wherein at least one of ABD1 , ABD2, ABD3 and ABD4 binds to a capsid of an adeno- associated virus (AAV) particle, and the other(s) of ABD1 , ABD2, ABD3, and ABD4 bind to a molecule on a cell surface.

132. The multispecific antibody or multispecific antigen-binding fragment of claim 131 , wherein two of ABD1 , ABD2, ABD3, and ABD4 bind to a capsid of an AAV particle, and two of ABD1 , ABD2, ABD3 and ABD4 binds to a molecule on a cell surface.

133. The multispecific antibody or multispecific antigen-binding fragment of claim 132, wherein ABD1 and ABD2 bind to a capsid of an AAV particle, and ABD3 and ABD4 binds to a molecule on a cell surface.

134. The multispecific antibody or multispecific antigen-binding fragment of claim 132, wherein ABD3 and ABD4 bind to a capsid of an AAV particle, and ABD1 and ABD2 binds to a molecule on a cell surface.

135. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 131-134, wherein the first scFv and / or second scFv is linked to the Fc domain via a linker.

136. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) a first heavy chain region of a first Fab (“Fab1”) operably linked to (ii) a second heavy chain region of a second Fab (“Fab2”) operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a third heavy chain region of a third Fab (Tab3) operable liked to (ii) a fourth heavy chain region of a fourth Fab (“Fab4”) operably linked to (iii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1 , wherein Fab1 comprises a first antigen-binding domain (“ABD1”); d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain (“ADB2”);e) a fifth polypeptide chain comprising a third light chain that pairs with the third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain (“ABD3”); and f) a sixth polypeptide chain comprising a fourth light chain that pairs with the fourth heavy chain region to form Fab4, wherein Fab 4 comprises a fourth antigen-binding domain (“ABD4”); wherein at least one of ABD1 , ABD2, ABD3 and ABD4 binds to a capsid of an adeno- associated virus (AAV) particle, and the other(s) of ABD1 , ABD2, ABD3, and ABD4 bind to a molecule on a cell surface.

137. The multispecific antibody or multispecific antigen-binding fragment of claim 136, wherein two of ABD1 , ABD2, ABD3, and ABD4 bind to a capsid of an AAV particle, and two of ABD1 , ABD2, ABD3 and ABD4 binds to a molecule on a cell surface.

138. The multispecific antibody or multispecific antigen-binding fragment of claim 137, wherein ABD1 and ABD3 bind to a capsid of an AAV particle, and ABD2 and ABD4 binds to a molecule on a cell surface.

139. The multispecific antibody or multispecific antigen-binding fragment of claim 137, wherein ABD2 and ABD4 bind to a capsid of an AAV particle, and ABD1 and ABD3 binds to a molecule on a cell surface.

140. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 136-139, wherein the first heavy chain region is linked to the second heavy chain region and / or the third heavy chain region is linked to fourth heavy chain region via a linker.

141. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 126-140, wherein the at least one of ABD1 , ABD2, ABD3, and ABD4 which binds to a capsid of an AAV particle comprises: a) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1159, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; f) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10; and / or j) a heavy chain variable region (HCVR) that comprises a HCDR1 , HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a light chain variable region (LCVR) that comprises a LCDR1 , LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

142. The multispecific antibody or multispecific antigen-binding fragment of claim 141 , wherein the at least one of ABD1 , ABD2, ABD3, and ABD4 which binds to a capsid of an AAV particle comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and a HCDR3 comprising the amino acidsequence of SEQ ID NO: 8; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 28; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 38; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 48; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 67; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 87; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3comprising the amino acid sequence of SEQ ID NO: 16; i) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 97; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; and / or j) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 107; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

143. The multispecific antibody or multispecific antigen-binding fragment of claim 141 or 142, wherein the at least one of ABD1 , ABD2, ABD3, and ABD4 which binds to a capsid of an AAV particle comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 2, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) a HCVR comprising the amino acid sequence of SEQ ID NO: 22, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) a HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) a HCVR comprising the amino acid sequence of SEQ ID NO: 42, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) a HCVR comprising the amino acid sequence of SEQ ID NO: 52 or 1 159, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1 157; f) a HCVR comprising the amino acid sequence of SEQ ID NO: 62, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) a HCVR comprising the amino acid sequence of SEQ ID NO: 71 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) a HCVR comprising the amino acid sequence of SEQ ID NO: 81 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) a HCVR comprising the amino acid sequence of SEQ ID NO: 91 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10; and / or j) a HCVR comprising the amino acid sequence of SEQ ID NO: 101 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

144. The multispecific antibody or multispecific antigen-binding fragment of any one ofclaims 126-143, wherein said molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel auxiliary subunit gamma 1 (CACNG1).

145. The multispecific antibody or multispecific antigen-binding fragment of claim 144, wherein said molecule on the cell surface is ASGR1 .

146. The multispecific antibody or multispecific antigen-binding fragment of claim 145, wherein the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to ASGR1 comprises: a) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157; or b) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

147. The multispecific antibody or multispecific antigen-binding fragment of claim 145 or 146, wherein the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to ASGR1 comprises: a) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 226; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or b) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 236; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

148. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 145-147, wherein the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to ASGR1 comprises: a) a HCVR comprising the amino acid sequence of SEQ ID NO: 220 or 1239, and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 10 or 1 157; or b) a HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 10.

149. The multispecific antibody or multispecific antigen-binding fragment of claim 144, wherein said molecule on the cell surface is TfR.

150. The multispecific antibody or multispecific antigen-binding fragment of claim 149, wherein the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to TfR comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 319 or 320;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 377;1 1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVRthat comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVRcomprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 51 1 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR that comprisesthe LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599;32) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1 119, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

151. The multispecific antibody or multispecific antigen-binding fragment of claim 149 or 150, wherein the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to TfR comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 274; and / or a LCDR1 comprising the amino acid sequence of SEQID NO: 277, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 279;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 285; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 290;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 296; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 301 ;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 306; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 311 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 312;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 317; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 321, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 323;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 329; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 335;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 341 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 347;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 351 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 353; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 359;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 364; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 369;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 375; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 380;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 385; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 390;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 396; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 401 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 402;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 407; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 411 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 412;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 417; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 421 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 422;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 428; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 434;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and a HCDR3 comprising the amino acidsequence of SEQ ID NO: 439; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 444;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 450; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 455;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 460; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 465;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 471 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 477;20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 481 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 483; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 488;21) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 494; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 499;22) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 503, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 504; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 509;23) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 514; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and a LCDR3comprising the amino acid sequence of SEQ ID NO: 519;24) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 524; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 529;25) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 534; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 539;26) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 545; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 550;27) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 555; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 560;28) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 565; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 570;29) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 575; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 578, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 580;30) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 585; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 590;31) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, a HCDR2 comprisingthe amino acid sequence of SEQ ID NO: 595, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 596; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 601 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 602;32) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 607; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 61 1 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 613; or33) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 121 , a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1 123, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1 125; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1 129, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1131 , and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1133.

152. The multispecific antibody or multispecific antigen-binding fragment thereof of any one of claims 149-151 , wherein the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to TfR comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 270 or 271 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 276;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 281 or 282, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 287;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 292 or 293, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 298;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 308 or 309;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 319 or 320;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 325 or 326, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 331 or 332;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 337 or 338, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 343 or 344;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 349 or 350, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 355 or 356;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 361 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 366;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 371 or 372, and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 377;11) a HCVR comprising the amino acid sequence of SEQ ID NO: 382, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 387;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 392 or 393, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 398 or 399;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 409;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 419;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 424 or 425, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 430 or 431 ;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 441 ;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 446 or 447, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 452;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 462;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 467 or 468, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 473 or 474;20) a HCVR comprising the amino acid sequence of SEQ ID NO: 479 or 480, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 485;21) a HCVR comprising the amino acid sequence of SEQ ID NO: 490 or 491 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 496;22) a HCVR comprising the amino acid sequence of SEQ ID NO: 501 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 506;23) a HCVR comprising the amino acid sequence of SEQ ID NO: 511 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 516;24) a HCVR comprising the amino acid sequence of SEQ ID NO: 521 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 526;25) a HCVR comprising the amino acid sequence of SEQ ID NO: 531 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 536;26) a HCVR comprising the amino acid sequence of SEQ ID NO: 541 or 542, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 547;27) a HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 557;28) a HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 567;29) a HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 577;30) a HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 587;31) a HCVR comprising the amino acid sequence of SEQ ID NO: 592 or 593, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 598 or 599 ;32) a HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 609 or 610; or33) a HCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

153. The multispecific antibody or multispecific antigen-binding fragment of claim 144, wherein said molecule on the cell surface is CACNG1.

154. The multispecific antibody or multispecific antigen-binding fragment of claim 153, wherein the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to CACNG1 comprises:1) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 803;11) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVRcomprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181 , and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or20) a HCVR that comprises the HCDR1 , HCDR2 and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR that comprises the LCDR1 , LCDR2 and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

155. The multispecific antibody or multispecific antigen-binding fragment of claim 153 or 154, wherein the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to CACNG1 comprises:1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 621 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 629;2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 641 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 649;3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 661 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 669;4) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 681 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 689;5) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 701 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 709;6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 721 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 729;7) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 741 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 745, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 749;8) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 761 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 769;9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 781 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 789;10) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and a HCDR3 comprising the amino acidsequence of SEQ ID NO: 801 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 809;11) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 821 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 829;12) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 841 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 849;13) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 861 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 869;14) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 881 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 889;15) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 901 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 909;16) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 921 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 929;17) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 941 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and a LCDR3comprising the amino acid sequence of SEQ ID NO: 949;18) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 961 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 969;19) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 183, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1 185, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1 187; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1 191 , a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1193, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195; or20) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1207, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1209, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 121 1 ; and / or a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1215, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1217, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1219.

156. The multispecific antibody or multispecific antigen-binding fragment thereof of any one of claims 153-155, wherein the other(s) of ABD1 , ABD2, ABD3, and ABD4 which binds to CACNG1 comprises:1) a HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 623;2) a HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 643;3) a HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 663;4) a HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 683;5) a HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 703;6) a HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 723;7) a HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 743;8) a HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 763;9) a HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or a LCVRcomprising the amino acid sequence of SEQ ID NO: 783;10) a HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 803;11) a HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 823;12) a HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 843;13) a HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 863;14) a HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 883;15) a HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 903;16) a HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 923;17) a HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 943;18) a HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 963;19) a HCVR comprising the amino acid sequence of SEQ ID NO: 1181 , and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or20) a HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or a LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

157. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 54, 58, 79, 84, 89, 94, 99, 104, 109, 130, 135, and 140, wherein the linker is:(a) at least 5 amino acids, at least 6 amino acids or at least 7 amino acids in length; and optionally(b) up to 30 amino acids, up to 40 amino acids, up to 50 amino acids or up to 60 amino acids in length.

158. The multispecific antibody or multispecific antigen-binding fragment of claim 157, wherein the linker is:(a) 5 amino acids to 50 amino acids in length;(b) 5 amino acids to 45 amino acids in length;(c) 5 amino acids to 40 amino acids in length;(d) 5 amino acids to 35 amino acids in length;(e) 5 amino acids to 30 amino acids in length;(f) 5 amino acids to 25 amino acids in length; or(g) 5 amino acids to 20 amino acids in length.

159. The multispecific antibody or multispecific antigen-binding fragment of claim 157, wherein the linker is:(a) 6 amino acids to 50 amino acids in length;(b) 6 amino acids to 45 amino acids in length;(c) 6 amino acids to 40 amino acids in length;(d) 6 amino acids to 35 amino acids in length;(e) 6 amino acids to 30 amino acids in length;(f) 6 amino acids to 25 amino acids in length; or(g) 6 amino acids to 20 amino acids in length.

160. The multispecific antibody or multispecific antigen-binding fragment of claim 157, wherein the linker is:(a) 7 amino acids to 40 amino acids in length;(b) 7 amino acids to 35 amino acids in length;(c) 7 amino acids to 30 amino acids in length;(d) 7 amino acids to 25 amino acids in length;(e) 7 amino acids to 20 amino acids in length.

161. The multispecific antibody or multispecific antigen-binding fragment of claim 157, wherein the linker is 5 amino acids to 25 amino acids in length.

162. The multispecific antibody or multispecific antigen-binding fragment of claim 157, wherein the linker is 10 amino acids to 60 amino acids in length.

163. The multispecific antibody or multispecific antigen-binding fragment of claim 157, wherein the linker is 20 amino acids to 50 amino acids in length.

164. The multispecific antibody or multispecific antigen-binding fragment of claim 157, wherein the linker is 25 to 35 amino acids in length.

165. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 157-164, wherein the linker is or comprises a multimer of GnS (SEQ ID NO: 239) or SGn (SEQ ID NO: 240), where n is an integer from 1 to 10.The multispecific antibody or multispecific antigen-binding fragment of claim 165, wherein the linker is or comprises a multimer of G4S (SEQ ID NO: 242). The multispecific antibody or multispecific antigen-binding fragment of any one of claims 157-164, wherein the linker is or comprises two consecutive glycines (2Gly), three consecutive glycines (3Gly), four consecutive glycines (4Gly (SEQ ID NO: 243)), five consecutive glycines (5Gly (SEQ ID NO: 244)), six consecutive glycines (6Gly (SEQ ID NO: 245)), seven consecutive glycines (7Gly (SEQ ID NO: 246)), eight consecutive glycines (8Gly (SEQ ID NO: 247)) or nine consecutive glycines (9Gly (SEQ ID NO: 248)). The multispecific antibody or multispecific antigen-binding fragment of any one of claims 51-167, wherein one or more light chains are universal light chains. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 51-167, wherein a light chain constant region (CL) and a first heavy chain constant region (CH1) of one or more Fabs are in a CrossmAb arrangement. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28-169, which comprises an Fc heterodimer. The multispecific antibody or multispecific antigen-binding fragment of claim 170, wherein the Fc domains in the Fc heterodimer comprise knob-in-hole mutations as compared to a wild type Fc domain. The multispecific antibody or multispecific antigen-binding fragment of claim 171 , wherein one Fc domain in the Fc heterodimer comprises amino acid substitutions S354C and T366W (according to EU numbering) as compared to a wild type Fc domain, and the other Fc domain in the Fc heterodimer comprises amino acid substitutions Y349C, T366S, L368A, and Y407V (according to EU numbering) as compared to a wild type Fc domain. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 170-172, wherein at least one Fc domain in the Fc heterodimer comprises a star mutation as compared to a wild type Fc domain. The multispecific antibody or multispecific antigen-binding fragment of claim 173, wherein one Fc domain in the Fc heterodimer comprises amino acid mutations H435Rand / or Y436F (according to EU numbering) as compared to a wild type Fc domain. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28-174, wherein said capsid comprises one or more wild-type AAV capsid polypeptides. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28-174, wherein said capsid comprises one or more non-wild-type AAV capsid polypeptides. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28-176, which is a bispecific antibody or bispecific antigen-binding fragment thereof. A pharmaceutical composition comprising the multispecific antibody or multispecific antigen-binding fragment of any one of claims 28-177, and a pharmaceutically acceptable carrier or excipient. A molecular complex comprising an AAV particle bound to one or more antibodies and / or antigen-binding fragments of any one of claims 1-26. The molecular complex of claim 179, wherein said AAV particle comprises one or more mutations in one or more AAV capsid proteins inhibiting the natural tropism of said AAV particle. A pharmaceutical composition comprising the molecular complex of claim 179 or 180 and a pharmaceutically acceptable carrier or excipient. A method of preparing the molecular complex of claim 179 or 180, comprising incubating said AAV particle in the presence of said one or more antibodies and / or antigen-binding fragments under conditions allowing specific binding of said one or more antibodies and / or antigen-binding fragments to said AAV particle capsid. A molecular complex comprising an AAV particle bound to one or more multispecific antibodies and / or multispecific antigen-binding fragments of any one of claims 28-177. The molecular complex of claim 183, wherein said AAV particle comprises one or moremutations in one or more AAV capsid proteins inhibiting the natural tropism of said AAV particle. A pharmaceutical composition comprising the molecular complex of claim 183 or 184 and a pharmaceutically acceptable carrier or excipient. A method of preparing the molecular complex of claim 183 or 184, comprising incubating said AAV particle in the presence of said one or more multispecific antibodies and / or multispecific antigen-binding fragments under conditions allowing specific binding of said one or more multispecific antibodies and / or multispecific antigen-binding fragments to said AAV particle capsid. A method for targeting an AAV particle to a cell expressing a molecule on the cell surface, comprising contacting the cell with the molecular complex of claim 183 or the pharmaceutical composition of claim 185, wherein said molecular complex comprises one or more multispecific antibodies and / or multispecific antigen-binding fragments which bind to said molecule on the cell surface. A method for delivering a polynucleotide to a cell expressing a molecule on the cell surface, comprising contacting the cell with the molecular complex of claim 183 or the pharmaceutical composition of claim 185, wherein said molecular complex comprises the AAV particle comprising said polynucleotide and bound to one or more multispecific antibodies and / or multispecific antigen-binding fragments which bind to said molecule on the cell surface. The method of claim 187 or claim 188, wherein said cell is in a subject and said molecular complex is administered to the subject. The method of any one of claims 187-189, wherein said AAV particle does not target said cell in the absence of said one or more multispecific antibodies and / or multispecific antigen-binding fragments.

Images